Age-associated changes in the neuroinflammatory response to toll-like receptor 4 and 9 stimulation

Leah Beth Christensen

University of Montana, Missoula
AGE-ASSOCIATED CHANGES IN THE NEUROINFLAMMATORY RESPONSE

TO TOLL-LIKE RECEPTOR 4 AND 9 STIMULATION

IN YOUNG MICE

By

LEAH BETH CHRISTENSEN

Bachelors of Science, Microbiology, University of Minnesota, Minneapolis, MN, 2007

Dissertation

presented in partial fulfillment of the requirements
for the degree of

Doctor of Philosophy
in Integrative Microbiology and Biochemistry, Cellular and Molecular Biology

The University of Montana
Missoula, MT

May 2013

Approved by:

Dr. Sandy Ross, Dean of the Graduate School
Graduate School

Dr. Scott Wetzel, Co-Chair
Division of Biological Sciences

Dr. Byron Caughey, Co-Chair
Laboratory of Persistent Viral Disease, RML, NIAID, NIH /
Division of Biological Sciences

Dr. D. Scott Samuels,
Division of Biological Sciences

Dr. Jesse Hay
Division of Biological Sciences
Dr. Karin Peterson
Laboratory of Persistent Viral Disease, RML, NIAID, NIH /
Division of Biological Sciences

Dr. Sue Priola
Laboratory of Persistent Viral Disease, RML, NIAID, NIH /
Department of Biomedical and Pharmaceutical Sciences
Age-associated changes in the neuroinflammatory response to Toll-like receptor 4 and 9 stimulation in young mice

Co-Chairperson: Scott Wetzel, Ph.D.

Co-Chairperson: Byron Caughey, Ph.D.

During the perinatal time period, the mammalian brain is developing rapidly and is particularly sensitive to inflammation. Inflammation during this time period may be linked to later neurological illness in humans. Disease-associated alterations in learning and behavior can be modeled in rodents using perinatal immune stimulation with either infectious agents or Toll-like receptor (TLR) agonists. Although the gestational period is a particularly sensitive time for neurodevelopment, it is not known for how long after birth this sensitivity persists. In mice, susceptibility to neurological infection declines dramatically during the first weeks of life. Therefore, we sought to compare the neuroinflammatory responses of neonatal and weanling mice. To do so, we injected neonatal and weanling mice intracerebrally (IC) with lipopolysaccharide (LPS) or CpG oligonucleotides (CpG), ligands of TLRs 4 and 9, respectively. We compared the production of inflammatory mediators and immune cell activation in the brain at each age. Despite lower Tlr mRNA expression in neonatal brains, TLR4 and TLR9 stimulation induced substantially higher levels of some cytokines in neonatal brains. We also detected age-associated differences in expression of a subset of microglial activating and inhibitory receptors, as well as age-associated differences in the immune populations present in the brain. We specifically examined whether the prion protein, PrP<sup>C</sup>, plays an immunomodulatory role in the brain. PrP<sup>C</sup> expression influences immune cell activation in the periphery, increases in the brain with age, and influences several aspects of glial cell function. Since glia are the primary immune-responsive cells in the brain, we hypothesized that PrP<sup>C</sup> would influence the neuroinflammatory response. However, we found no PrP<sup>C</sup>-dependent differences in cytokine production or glial activation in vivo in neonatal or weanling mice. Collectively, our data demonstrate that the neuroinflammatory response to TLR stimulation is developmentally regulated in young mice, although independent of PrP<sup>C</sup> expression.

~ iii ~
ACKNOWLEDGMENTS

I would like to start by thanking my advisor, Dr. Byron Caughey, for welcoming me into his lab, and for his guidance, encouragement, and giving me the freedom to explore new projects. I would also like to thank Dr. Karin Peterson for her assistance and invaluable insight. Thank you to my other committee members for taking the time to meet over the years, and for providing valuable input and discussion. I would like to thank former and current members of the Caughey and Peterson labs for your assistance, patience, and for creating such an enjoyable work environment. I would also like to thank DBS faculty and staff, who have always been helpful and welcoming.

I would especially like to thank my husband, Kevin, for his unconditional support and love, for his patience, flexibility and willingness to move to rural Montana, where there are no fine dining restaurants. Thank you to my parents and my sister, who have always believed in me and supported my every endeavor, no matter how unexpected. I would like to thank my little boys, Jack and Caleb, who inspire me and fill me with endless joy. Lastly, I would like to thank the many wonderful friends I have made here in Montana.
# TABLE OF CONTENTS

151 ABSTRACT iii
152 ACKNOWLEDGMENTS iv
153 TABLE OF CONTENTS v
154 LIST OF TABLES viii
155 LIST OF FIGURES ix
156 CHAPTER ONE: Introduction 1
157 Cells of the central nervous system 1
158 The neonatal immune system 3
159 Origins of CNS myeloid cell populations 3
160 CNS myeloid cell functionality 4
161 Surveillant and activated microglia 6
162 Toll-like receptors 7
163 TLR signaling 8
164 TLR signaling in development 11
165 The neonatal TLR response is stimulus and cell type-specific 12
166 Prion protein and transmissible spongiform encephalopathies (TSEs) 13
167 TLR signaling influences the scrapie incubation period 14
168 Overview 14
169 Figures 16
170 CHAPTER TWO: Supporting data for analysis of age-associated changes in neuroinflammatory response 19
171 Results 19
| 174 | Background studies on the influence of age and agonist concentration on in vivo cytokine production | 19 |
| 175 | Developing a flow cytometry protocol for analysis of LPS-stimulated CNS immune populations | 20 |
| 177 | Flow cytometry on astrocytes ex vivo | 24 |
| 180 | Discussion | 25 |
| 181 | Figures | 27 |
| 184 | CHAPTER THREE: Age-associated changes in the acute neuroinflammatory response to Toll-like receptor 4 and 9 stimulation in young mice | 35 |
| 186 | Introduction | 35 |
| 187 | Results | 37 |
| 188 | Neonatal cytokine responses to TLR4 stimulation are heightened and sustained | 37 |
| 189 | Age-dependent differences in expression of inflammatory signaling markers | 40 |
| 191 | Glia contribute to heightened neonatal responses to TLR4 and TLR9 stimulation | 41 |
| 197 | Age-associated expression of microglial activating and inhibitory receptors | 43 |
| 198 | Discussion | 48 |
| 199 | Tables | 54 |
| 200 | Figures | 57 |
| 201 | CHAPTER FOUR: Prion protein and the neuroinflammatory response to Toll-like receptor 4 and 9 stimulation in young mice | 72 |
| 204 | Introduction | 72 |
| 205 | Results | 74 |
| 206 | PrP<sup>C</sup> expression in the brain changes with age but not in response to LPS or CpG stimulation | 74 |

~ vi ~
208 Tlr4 and Tlr9 gene expression is not affected by a lack of PrPc under homeostatic or inflammatory conditions.

210 Lack of effect of PrPc expression on cytokine responses to IC TLR4 or TLR9 stimulation.

212 PrPc expression did not influence glial activation.

214 Discussion

216 Figures

217 CHAPTER FIVE: EXPERIMENTAL METHODS

219 Tables

221 CHAPTER SIX: CONCLUDING REMARKS

222 References
LIST OF TABLES

240  Table 3.1 Summary of age-associated changes in cytokine responses 54
241  Table 3.2 Phenotypes of observed CNS immune populations 55
242  Table 3.3 Percentage of cells in examined populations 56
243  Table 6.1 Primers used for qRT-PCR 94
244  Table 6.2 Antibodies used for flow cytometry 96

~ viii ~
# LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.1</td>
<td>Microglial morphology is influenced by age and previous immune challenge</td>
<td>16</td>
</tr>
<tr>
<td>Figure 1.2</td>
<td>Activated TLR4 signals from the plasma membrane and the endosome</td>
<td>17</td>
</tr>
<tr>
<td>Figure 1.3</td>
<td>Activated TLR9 signals from the endosome</td>
<td>18</td>
</tr>
<tr>
<td>Figure 2.1</td>
<td>Determination of LPS dosage for IC inoculations</td>
<td>27</td>
</tr>
<tr>
<td>Figure 2.2</td>
<td>Cytokine response is dependent on age and TLR agonist</td>
<td>28</td>
</tr>
<tr>
<td>Figure 2.3</td>
<td>LPS-stimulated cells isolated using myelin depletion columns are poorly detected by flow cytometry</td>
<td>29</td>
</tr>
<tr>
<td>Figure 2.4</td>
<td>Enrichment of astrocytic and microglial populations in separate Percoll gradient fractions</td>
<td>30</td>
</tr>
<tr>
<td>Figure 2.5</td>
<td>Comparison of cell populations isolated using myelin depletion columns and Percoll gradients</td>
<td>31</td>
</tr>
<tr>
<td>Figure 2.6</td>
<td>Comparison of CNS immune populations isolated using myelin depletion columns and Percoll gradients</td>
<td>32</td>
</tr>
<tr>
<td>Figure 2.7</td>
<td>Enzymatic digest improves detection of LPS-stimulated CNS immune cells</td>
<td>33</td>
</tr>
<tr>
<td>Figure 2.8</td>
<td>Flow cytometry of astrocytes <em>ex vivo</em></td>
<td>34</td>
</tr>
<tr>
<td>Figure 3.1</td>
<td>Cytokine responses to IC TLR4 and TLR9 stimulation are heightened in neonates</td>
<td>57</td>
</tr>
<tr>
<td>Figure 3.2</td>
<td>Production of some cytokines does not differ with age in response to IC LPS or CpG</td>
<td>59</td>
</tr>
<tr>
<td>Figure 3.3</td>
<td>Heightened and prolonged inflammatory cytokine responses in neonates</td>
<td>60</td>
</tr>
<tr>
<td>Figure 3.4</td>
<td>Age-associated differences in expression of signaling markers</td>
<td>61</td>
</tr>
<tr>
<td>Figure 3.5</td>
<td>Temporal expression of glial and immune cell markers after TLR4</td>
<td>62</td>
</tr>
</tbody>
</table>
Both astrocyte- and microglia-enriched fractions contribute to heightened expression of inflammatory genes in neonates.

Cell population gates used for analysis of flow cytometry data.

CNS immune cell populations.

Increased expression of activating and inhibitory markers on neonatal microglia.

SLAMF7 is strongly expressed by neonatal microglia.

Increased expression of immune markers in the spleen after IC LPS administration.

Brain PrP<sup>c</sup> expression is influenced by age but not TLR4 or TLR9 stimulation.

TLR mRNA expression is influenced by age but not PrP<sup>c</sup> expression.

PrP<sup>c</sup> expression does not alter cytokine responses to TLR4 or TLR9 stimulation in neonatal brains.

PrP<sup>c</sup> expression does not alter cytokine responses to TLR4 or TLR9 stimulation in weanling brains.

PrP<sup>c</sup> over expression does not influence cytokine responses to TLR9 stimulation in weanling brains.

PrP<sup>c</sup> expression does not impact expression of glial activation markers in response to LPS or CpG.

~ X ~
CHAPTER ONE

INTRODUCTION

Cells of the central nervous system

Neurons, astrocytes and oligodendrocytes in the central nervous system (CNS) arise from a common neuroepithelial progenitor cell. In contrast, microglia, the other prominent CNS cell type, are of myeloid origin. In humans, neurons constitute about half of the brain’s cells (Azevedo et al., 2009; Lent et al., 2012). Glial cells—oligodendrocytes, astrocytes, and microglia largely account for the rest of the brain’s cells, with a small percentage being epithelial and endothelial cells. In the human cortex, which is responsible for higher brain function, approximately 75% of glial cells are oligodendrocytes, about 20% are astrocytes and 5% are microglia (Pelvig et al., 2008). Despite accounting for a relatively small percentage of the brain’s cells, astrocytes and microglia perform critical roles during development, disease and maintenance of homeostatic conditions. The percentage of each cell type in the rodent brain is not as well studied.

Neurons are highly specialized cells that transmit and accept electrical impulses and neurotransmitters. Neurotransmission occurs at specialized cellular junctions called synapses. Most neurons are terminally differentiated and generation of new neurons from neuroprogenitor cells is limited in adults. In contrast with most tissues, which undergo regular cellular turnover, neurons exist for the lifetime of the animal. Thus, one of the main functions of microglia and astrocytes is to protect neurons and aid their recovery from damage and disease.
Oligodendrocytes produce myelin, which sheaths neuronal axons, allowing rapid transmittance of impulses from one neuron to another. In the peripheral nervous system, this role is filled by Schwann cells. Myelination is absolutely essential for proper nervous system function in vertebrates.

Astrocytic processes envelope neurological synapses and rapidly take up excess neurotransmitters after neurotransmission (Danbolt, 2001). Prolonged exposure of neurons to neurotransmitters quickly leads to neurotoxicity (Rosenberg and Aizenman, 1989). Astrocytes also promote neuronal health by producing neurotrophic factors (Airaksinen and Saarma, 2002; Petrova et al., 2003; Rudge et al., 1995). Astrocytes are a critical part of the blood-brain-barrier (BBB) (Pekny et al., 1998; Wolburg and Lippoldt, 2002). Astrocytic endfeet are the primary component of the glia limitans, which separates the perivascular space from the brain parenchyma, or tissue proper (Bechmann et al., 2007). Although not considered an immune cell, astrocytes can produce inflammatory mediators, including cytokines and chemokines, in response to infection and damage (Bolin et al., 2005; Butchi et al., 2008; Butchi et al., 2010).

Microglia are the primary immune sentinels of the CNS. In addition to responding to pathogens and promoting inflammation, microglia clear cellular debris, and release trophic and anti-inflammatory factors that resolve the inflammatory response (Bessis et al., 2007; Prinz et al., 2011; Saijo and Glass, 2011). Microglia are involved in CNS development. They promote neurogenesis and synaptogenesis (Roumier et al., 2004; Sierra et al., 2010). Microglia also regulate synaptic pruning and programmed cell death of excess neurons (Frade and Barde, 1998; Paolicelli et al., 2011; Stevens et al., 2007; Wakselman et al., 2008).
The neonatal immune system

In some respects, the neonatal immune response is immature when compared with its adult counterpart. For example, immunological memory is not yet developed. However, in many ways the neonatal immune system is not immature as much as it is responding to the unique demands of its environment. At birth neonates are moving from a sterile intrauterine environment to one in which microbes, both pathogenic and commensal, are ubiquitous (Levy, 2007). The skin and gut, being subject to immediate colonization after birth, display a distinct immune response that balances the risk of infection with the danger of responding too strongly to commensal microbes (Dorschner et al., 2003; Lotz et al., 2006; Tollin et al., 2005). In the blood of neonates, some acute phase proteins are heightened in response to the mild hypoxia that results from normal labor and delivery (Jokic et al., 2000; Levy et al., 2006a). As a final example of the unique demands placed on the neonatal immune system, many inflammatory proteins have additional functions in neurological development. Complement proteins mediate neurogenesis and migration of neuroprogenitors to their proper location (Rutkowski et al., 2010). The cytokine IL-6 promotes neurite growth in vitro. Many immune molecules and cells are developmentally regulated during the period surrounding birth. In many tissues, neonatal immune stimulation can have consequences that differ from other ages (Chelvarajan et al., 2007; Ferret-Bernard et al.; Lotz et al., 2006).

Origins of CNS myeloid cell populations

Macrophages are highly heterogeneous cells that reside in every tissue in the body, their precise functions and capabilities dictated by the tissue they inhabit (Murray and Wynn,
Tissue-specific macrophages derive from multiple origins (Schulz et al., 2012). Early in fetal development, a portion of the tissue-specific macrophage populations arise from extra-embryonic yolk sac macrophages (Ginhoux et al., 2010; Schulz et al., 2012). Later in development, hematopoietic stem cells (HSCs) give rise to myeloid progenitors (MPs). MPs can differentiate into monocytes and tissue macrophages. Monocytes circulating in the blood may also enter tissues and differentiate into macrophages (Auffray et al., 2007). Thus, tissue-specific macrophages may originate from yolk sac macrophages, HSCs, and blood monocytes.

In the CNS, cells of myeloid origin include microglia and macrophages. CNS macrophages reside within the perivasculation, meninges and choroid plexus. Resident macrophages derive from, and are regularly replenished by, blood monocytes (Bechmann et al., 2001; Chinnery et al., 2010). Microglia are the only CNS myeloid cells that reside beyond the blood brain barrier (BBB) in the brain parenchyma. Microglia probably differentiate from yolk sac macrophages and HSCs, although the precise contribution of each precursor to the microglial population is currently a matter of debate (Ginhoux et al., 2010; Samokhvalov et al., 2007; Schulz et al., 2012). In mice, the microglial population increases sixteen-fold during the first two post-natal weeks (Alliot et al., 1999). These new microglia derive from dividing resident microglia (Ginhoux et al., 2010). Microglia are one of the few tissue macrophage populations replenished through self-renewal and not blood-derived monocytes.

**CNS myeloid cell functionality**

Research has demonstrated important functional differences between the populations of CNS myeloid cells (El Khoury et al., 2007; Mildner et al., 2011; Simard et al., 2006).
Parenchymal microglia differ from resident macrophages in several ways. In addition to deriving, at least partially, from a different progenitor cell and being replenished by self-renewal, microglia express different patterns of cell surface markers than other CNS myeloid cells (Ransohoff and Cardona, 2010). Immune cell markers are frequently expressed at lower levels on microglia. For example, microglia express little MHC class II, which is in line with their reduced ability to present antigen. In contrast, resident macrophages are able to present antigens to T cells that have been previously activated in peripheral tissues (Hickey and Kimura, 1988). Unlike other myeloid cells, microglia express ion channels, neurotransmitter receptors, and a greater range of purinoceptors (Färber and Kettenmann, 2005; Färber and Kettenmann, 2006; Hanisch and Kettenmann, 2007).

Blood monocytes may be stimulated to enter the brain parenchyma under experimental conditions (Mildner et al., 2007; Simard et al., 2006). When this occurs they can differentiate into microglia-like cells. However, they have different functional capabilities than microglia. For example, blood monocytes are better able to phagocytize Aβ fibrils (El Khoury et al., 2007). Whether blood monocytes are able to enter the brain parenchyma in human neurological conditions is unclear.

Neonatal microglia are thought to exist in an elevated activation state due to their developmental roles in this time period (Bilbo and Schwarz, 2009). Whether neonatal CNS macrophages also have specific developmental roles that would influence their activation state in neonates is unknown. Thus, microglia, as well as resident macrophages, may contribute to age-dependent differences in responses to immune stimulation. It is also unclear whether age-associated differences in recruitment of blood monocytes occur after TLR stimulation (Levy,
While neonatal monocytes are known to respond differently than adult monocytes in peripheral responses to immune stimulation, they may also behave differently than resident microglia (Kollmann et al., 2009; Nguyen et al., 2010).

**Surveillant and activated microglia**

Under normal conditions, microglia are often described as “resting” or “quiescent”. These descriptions, which imply a degree of dormancy, are based on physical appearance and do not give an accurate indication of the cells’ activity level. It is more accurate to refer to resting microglia as surveillant because they are active, but not in the proinflammatory way that is traditionally meant when microglia are described as active (Prinz et al., 2011). Surveillant microglia have a ramified phenotype, with many fine processes that are highly motile, constantly surveying their local environment for signs of disease or damage (Nimmerjahn et al., 2005). Their physical appearance is very different from “activated” microglia, which have retracted their processes and taken on an amoeboid appearance that is more similar to a typical macrophage. Amoeboid microglia have generally been activated by inflammation, produce large amounts of inflammatory molecules, and are highly phagocytic (Saijo and Glass, 2011). The switch from surveillant to amoeboid is not an all or nothing phenomenon. Activated microglial phenotypes often exist as gradations between ramified and amoeboid (Graeber, 2010). Complete retraction of processes into a fully amoeboid morphology is rare. Healthy microglia return to a ramified phenotype once the situation requiring their activation is resolved. Neonatal microglia have an amoeboid morphology, which is correlated with increased phagocytic ability (Fig 1.1). In contrast, weanling microglia have a ramified
phenotype with many fine processes. When microglia become over-activated by excessive inflammatory stimulation, they may be unable to transition to a surveillant state and instead chronically produce pro-inflammatory mediators, leading to significant tissue damage over time. This may occur in immune-stimulated neonatal microglia (Bilbo and Schwarz, 2009).

Chronically over-activated microglia are not amoeboid but instead have several extremely thick processes (Bilbo and Schwarz, 2009). Additionally, acute encephalitic conditions can lead to activated microglia possessing a long and slender rod cell phenotype (Ackman et al., 2006; Graeber, 2010).

**Toll-like receptors**

Toll-like receptors (TLRs) are pattern recognition receptors (PRRs), a large and diverse family of proteins united in their ability to recognize pathogen-associated molecular patterns (PAMPs). PRR binding is often the first step in immune recognition and response to an invading pathogen. TLR stimulation activates production of cytokines and anti-microbial effector molecules (West et al., 2006). TLRs are prominently expressed on immune cells such as monocytes, macrophages and DCs (West et al., 2006). In the central nervous system (CNS), they are expressed on astrocytes and microglia and, to a lesser extent, neurons (McKimmie and Fazakerley, 2005). TLRs localize to either the plasma membrane or endosomal membranes (Barton and Kagan, 2009; Kagan et al., 2008). Plasma membrane-associated TLRs, such as TLR4, recognize components of bacterial outer membranes and viral envelopes. Endosomal TLRs, such as TLR9, recognize microbial nucleic acids. We have focused on TLR4 and TLR9 stimulation with their ligands, lipopolysaccharide (LPS) and CpG-rich oligonucleotides (CpG), respectively.
We chose TLRs 4 and 9 due to their potential to interact with the prion protein. This will be discussed further in chapter three.

**TLR signaling**

TLR4 signaling is often used as a model for TLR signaling because it is well-studied and TLR4 signals from both the plasma membrane and endosome (Fig 1.2). TLR4 stimulation leads to the production of pro-inflammatory cytokines through activation of several intracellular signaling pathways (Barton and Kagan, 2009; Ostuni et al., 2010). Upon ligand binding at the plasma membrane, TLR4 signaling leads to an initial activation of the transcription factors NFκB and AP-1. The TLR4 complex is then endocytosed. From the endosome, TLR4 stimulates a second round of NFκB and AP-1 activation, as well as activation of the transcription factor IRF3. The first round of NFκB and AP-1 activation is mediated by the adaptor MyD88. The second round of TLR4-mediated transcription factor activation is mediated by TRIF rather than MyD88. NFκB and AP-1 activation leads to the production of pro-inflammatory cytokines, with the exception of the type I interferons, which are induced by IRF3.

TLR signaling is complex; the precise outcomes of ligand binding are influenced by numerous intracellular adaptor proteins, which are modulated by the host cell's differentiation and activation state. Two features that guide TLR signaling are membrane phospholipid composition and polyubiquitin scaffolds. Membrane phospholipids control the cellular location of the TLR4 complex and provide binding sites for necessary intracellular adaptors (Kagan and Medzhitov, 2006; Triantafilou et al., 2004). Polyubiquitin scaffolds provide docking sites for
intracellular proteins critical to the activation of downstream transcription factors (Deng et al., 2000; Fan et al., 2010).

Recognition of LPS by TLR4 is aided by several accessory proteins. The secreted LPS binding protein (LBP) sequesters LPS monomers and presents them to CD14, which has an extremely high affinity for LPS (Gioannini et al., 2004; Wright et al., 1990). At the plasma membrane, CD14 transfers LPS to the TLR4:MD-2 complex (Gioannini et al., 2004). Concurrent with TLR4:MD-2 stimulation, CD14 interacts with CD11b (CR3) (Zarewych et al., 1996). CD11b may promote synthesis of the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP$_2$) by the kinase PI(4)P5K (Hynes, 2002; Ostuni et al., 2010). In response to TLR4 ligand binding, both PIP$_2$ and TLR4 are concentrated in lipid rafts. TLR4 is not normally found in lipid rafts but must be recruited and retained there for effective TLR signaling (Triantafilou et al., 2004).

On the cytosolic side of the plasma membrane, the sorting adaptor TIRAP is recruited by the relatively high concentrations of PIP$_2$ (Kagan and Medzhitov, 2006). TIRAP engages the signaling adaptor MyD88, which interacts sequentially with the IRAK effector proteins, leading to recruitment of the E3 ubiquitin ligase TRAF6 (Cao et al., 1996; Kagan and Medzhitov, 2006; Kawagoe et al., 2008; Suzuki et al., 2002). TRAF6 self polyubiquitination serves as a docking point for the IKK regulatory complex and the kinase TAK1 (Deng et al., 2000; Fan et al., 2010). Activated IKK promotes NFκB activation by phosphorylating IκB, leading to its degradation. NFκB, which is normally sequestered in the cytosol by IκB, is now able to translocate into the nucleus and induce pro-inflammatory gene expression (Doyle and O'Neill, 2006; Li and Stark, 2002). During inflammatory signaling, AP-1 activation is primarily regulated by the nuclear MAP kinases (MAPKs) p38, JNK, and ERK (Ostuni et al., 2010). Nuclear MAPK activation is connected
to the TLR signaling pathway by TAK1. As an activator of both IKK and the MAPKs p38 and JNK, TAK1 is the branching point at which AP-1 activation diverges from NFκB activation in the MyD88-dependent pathway (Sato et al., 2005; Wang et al., 2001).

The above events described for MyD88-dependent signaling from the plasma membrane occur within 15-30 minutes of stimulation (Husebye et al., 2006; Kagan et al., 2008). After this, the concentration of PIP$_2$ in the plasma membrane declines significantly, leading to endocytosis of the TLR4 signaling complex (Botelho et al., 2000; Ostuni et al., 2010). Decreased PIP$_2$ also results in TIRAP dissociating from the complex. With TIRAP gone, another sorting adaptor, TRAM, is able to bind the intracellular domain of TLR4 (Yamamoto et al., 2003). TRAM recruits the signaling adaptor TRIF, which engages the kinase RIP-1 (Meylan et al., 2004). From this point on, the events leading to late NFκB signaling are similar to those described for early NFκB signaling.

To activate IRF3, the signaling adaptor TRIF interacts with TRAF3, whose self-ubiquitination leads to IRF3 activation (Hacker et al., 2006). Under basal conditions, IRF3 is a cytosolic monomer but activating phosphorylation triggers dimerization and nuclear translocation, permitting induction of the type I interferons, IFN-α and IFN-β (Honda et al., 2006).

TLR4 signaling ends when the endosome matures. At this time the TRAM splice variant, TAG, displaces TRIF in binding to TRAM, leading to endolysosomal degradation of TLR4 (Husebye et al., 2006; Palsson-McDermott et al., 2009).

TLR9 recognizes bacterial and viral unmethylated CpG DNA. In unstimulated cells, TLR9 is found in the endoplasmic reticulum (ER) (Latz et al., 2004; Leifer et al., 2004). In response to
immune stimulation, the sorting protein UNC93B1 transports inactive TLR9 from the ER to the endolysosomal pathway (Kim et al., 2008; Tabeta et al., 2006). Upon entering the endolysosome, TLR9 is proteolytically cleaved (Ewald et al., 2008; Park et al., 2008). Notably, full-length TLR9 can bind CpG DNA but cannot bind the intracellular signaling adaptor protein MYD88 (Barton and Kagan, 2009; Ewald et al., 2008). Therefore, proteolytic cleavage regulates the ability of TLR9 to transmit immune stimulatory signaling. Upon ligand binding and proteolytic cleavage, TLR9 binds MYD88, which leads to downstream signaling similar to what was previously described for endosomal TLR4 signaling (Fig 1.3) (Barton and Kagan, 2009; West et al., 2006). TLR9 signaling culminates in induction of cytokine genes, including the interferons, and other inflammatory mediators.

**TLR signaling in development**

* Tlr4 and Tlr9 mRNA expression are developmentally regulated in the murine brain. In mice, brain Tlr9 expression increased from embryonic time points through adulthood (Kaul et al., 2012). In rats, brain Tlr4 mRNA expression increased from birth through adulthood (Ortega et al., 2011). However, TLR4 protein levels in the rat brain remained stable over the same time period (Ortega et al., 2011). Among peripheral immune populations, Tlr9 mRNA expression levels in human adult and cord blood monocytes were similar (Dasari et al., 2011), as were TLR9 protein levels on human plasmacytoid dendritic cells from adult peripheral blood and cord blood (Danis et al., 2008). Two human studies found no difference in monocytic Tlr4 expression between neonates and adults (Dasari et al., 2011; Levy et al., 2004). However, in young mice
(9-12 days old), macrophage TLR4 expression was decreased when compared with expression in adult macrophages (Chelvarajan et al., 2004).

A comprehensive analysis of TLR signaling pathway function in neonatal cells is complicated by the fact that studies are often done in different species, using different cell types and methods of harvesting cells, and different TLR ligands. Despite this, some general patterns are emerging: Cord blood monocytes have reduced MyD88 expression, p38 phosphorylation, and IRF3 activation when TLR stimulation leads to reduced cytokine output (Aksoy, 2006; Levy et al., 2004; Sadeghi et al., 2007; Yan et al., 2004). Enhanced cytokine production by cord blood monocytes is associated with increased p38 phosphorylation and IκB degradation (Levy et al., 2006b).

The neonatal TLR response is stimulus- and cell type-specific

Several cytokines, including IL-6 and IL-10, are elevated in neonates in numerous conditions and cell types outside the CNS (Angelone et al., 2006; Chelvarajan et al., 2004; Nguyen et al., 2010). In contrast, other cytokines, such as IL-1b, IL-12, TNF and the interferons, are often expressed at reduced levels in neonatal immune cells that are isolated from peripheral blood and tissues and stimulated with TLR agonists (Belderbos et al., 2009; Chelvarajan et al., 2004; Islam et al., 2012b; Marodi, 2006). However, research is increasingly showing that the neonatal cytokine response to TLR stimulation differs depending on the tissue and cell type stimulated, as well as the TLR ligand. For example, in whole human blood stimulated with LPS, production of IL-6, IL-8 and IL-10 was heightened in neonates when compared with adult blood (Nguyen et al., 2010). In comparison, when the TLR9 ligand CpG...
was used, in addition to IL-6, IL-8 and IL-10, IL-1β was also elevated (Nguyen et al., 2010). In sheep mesenteric lymph nodes, stimulation of TLR8 was able to potently overcome inhibition of T$_h$1-promoting responses to produce higher amounts of IL-12 and IFNγ in neonates than adults (Ferret-Bernard et al.). Stimulation with bacterial pathogens also leads to age-dependent cytokine responses in peripheral neonatal immune populations (Chelvarajan et al., 2007; Levy et al., 2006a).

**Prion protein and transmissible spongiform encephalopathies (TSEs)**

TSEs are a group of fatal neurodegenerative diseases that includes diseases of infectious, genetic, sporadic and iatrogenic origin (Caughey et al., 2009). TSE pathology and transmissibility requires expression of the endogenous prion protein (Bueler et al., 1993). In TSEs, the prion protein misfolds from its endogenous and non-pathogenic form, PrP$^c$, into a pathogenic form, PrP$^Sc$, whose name derives from the prototypical TSE, ovine scrapie. Conformationally, PrP$^c$ has higher α-helical content while PrP$^Sc$ contains reduced α-helix and increased levels of β-sheets. Although TSE disease progression has been closely studied, the underlying pathological causes remain unclear. Since misfolding of PrP$^c$ into PrP$^Sc$ may lead to subversion of normal function, knowledge of the normal function(s) of PrP$^c$ may enlighten our understanding of TSE pathology.

PrP$^c$ is a 254 amino acid protein that is glycosylated and primarily bound to the plasma membrane through a glycoposphatidyl inositol (GPI) anchor. Despite PrP$^c$’s apparent involvement in an array of physiological processes, its precise function remains poorly defined (Linden et al., 2008). Some proposed functions, such as adhesion and differentiation, are
applicable to many cell types and may reflect the near ubiquitous distribution of PrP^C. Others, such as mitigating excitotoxicity and acting as a scavenger receptor (Khosravani et al., 2008; Marc et al., 2007; Sunyach et al., 2003), could reflect functions in specific cell types like neurons and microglia. PrP^C functions associated with immunity and development are discussed in chapter three.

**TLR signaling influences the TSE incubation period**

Mice deficient in TLR4 signaling have a shortened scrapie incubation period (Spinner et al., 2008). Notably, MyD88 deficiency does not impact the scrapie incubation period (Prinz et al., 2003). This implies the MyD88-independent, TRIF-dependent TLR signaling pathway may influence scrapie disease progression. In agreement with this, a recently published paper demonstrates a shortened scrapie incubation period in mice lacking IRF3, a critical transcription factor in MyD88-independent signaling (Ishibashi et al., 2012). IRF3 activates many immune-responsive genes, including type I interferons. However, stimulation with interferons does not influence the scrapie incubation period (Field et al., 1969; Gresser et al., 1983). In addition, inoculation with the TLR9 ligand unmethylated CpG ODNs prolongs the scrapie incubation period (Sethi et al., 2002).

**Overview**

In mice, the neonatal brain is much more sensitive to infection than the weanling brain. Therefore, I hypothesized that the neuroinflammatory response would be altered in an age-dependent manner in mice. To model neuroinflammation, I injected neonatal and weanling
mice intracerebrally (IC) with either the TLR4 agonist LPS or the TLR9 agonist CpG ODN. I aimed to compare expression of some neuroinflammatory mediators, including a subset of cytokines, at each age in order to gain insight into how the immune response changes with age. I was particularly interested in examining the activation profiles of microglia, as they are important mediators of the inflammatory response in the brain and their activation may be influenced by age. Therefore, for my second aim, I compared expression of activating and inhibitory markers on neonatal and weanling mice. Lastly, I aimed to determine whether PrPc mediates neuroinflammation in an age-dependent manner, since PrPc expression increases with age and has previously been associated with various immunological functions.
Figure 1.1 Microglial morphology is influenced by age and previous immune challenge.

Summary of how microglial phenotype changes with age and in response to immune challenge in murine models of development and disease. Time line shown is for mouse development.

Figure 1.2 Activated TLR4 signals from the plasma membrane and the endosome. Ligand binding stimulates recruitment of TLR4 into lipid rafts, where early TLR signaling is initiated. Upon endocytosis, TLR4 activates late TLR signaling from the endosome. From Ostuni et. al., Cell. Mol. Life Sci., 2010.
Figure 1.3 Activated TLR9 signaling from the endosome. Ligand binding and proteolytic cleavage lead to TLR9 signaling from the endolysosomal pathway. From Kawai & Akira, Cell Death & Differentiation.
BACKGROUND STUDIES ON INFLUENCE OF AGE AND AGONIST CONCENTRATION ON IN VIVO CYTOKINE PRODUCTION

In previous studies using the IRW mouse strain, a strong neuroinflammatory response was observed in neonatal mice after intracerebral (IC) inoculation with 1 µg LPS per gram of body weight (Butchi et al., 2008). To determine the best concentration of LPS to use in neonatal C57Bl/10 mice for IC inoculations, we tested 0.25, 0.5 and 1 µg LPS per gram of body weight. Cytokine protein levels in brain tissue were measured using a multiplex bead assay. Representative data are shown in Figure 2.1. One microgram LPS per gram of body weight was fatal to nearly fifty percent of C57Bl/10 mice (Fig 2.1A). We observed a similar mortality rate in C57Bl/10 PrP−/− mice (data not shown). With the exception of IL-6 (p=0.0058), the cytokine response to 0.5 µg LPS per gram body weight did not differ significantly from the cytokine response to 1 µg LPS per gram of body weight (Fig 2.1B). However, at 0.5 µg LPS per gram body weight, all mice survived. Therefore, we used 0.5 µg LPS per gram body weight in all future treatments. We also halved the CpG concentration that had been used in IRW mice to 0.125 µg CpG (40 picomole) per gram of body weight, in case the C57Bl/10 mice were also more reactive to this TLR ligand.

To better understand how the cytokine response to TLR 4 and 9 stimulation develops with age, we also examined IL-6 and CCL2 production in 10 and 42 day old (d.o.) mice. We chose the 10 d.o. age because susceptibility to Sindbis virus infection of the CNS decreases
dramatically by 11 days of age (Trgovcich et al., 1999). Since 21 d.o. mice are not yet adult, we also examined how the weanling response differs from that of a 42 d.o. adult.

Figure 2.2 shows the IL-6 and CCL2 protein production in response to TLR4 or TLR9 stimulation in 2, 10, 21 and 42 d.o. mice. Although the 2 and 21 d.o. samples were analyzed separately from the 10 and 42 d.o. samples, standards were comparable between experiments. The IL-6 response to TLR4 stimulation consistently declined with age over the time course analyzed. The CCL2 response to TLR4 stimulation showed an overall decline with age, although CCL2 levels were slightly higher in 21 d.o. mice than 10 d.o. mice. CCL2 production in response to TLR9 stimulation dramatically decreased in mice beyond the neonatal time period and remained low. In contrast, IL-6 production decreased from 2 to 21 days of age but sharply increased in 42 d.o. mice. Collectively, these data suggest that production of IL-6 and CCL2 depends not only on age, but also on the type of immune stimulant.

Developing a flow cytometry protocol for analysis of LPS-stimulated CNS immune populations

Many, if not all, cell types in the central nervous system can produce cytokines. However, we expected microglia and astrocytes to be important cytokine-producing cells in the brain during the response to TLR4 stimulation (discussed in Chapters 1 and 2). Initially, we planned to use flow cytometry to characterize and compare the activation states of neonatal and weanling microglia and astrocytes. A major hurdle to flow cytometric analysis of brain cell populations ex vivo is myelin. Contaminating myelin ovoids can be similar in size and shape to cells, making it impossible to gate them out based on size. Myelin can also mask epitopes and
lead to non-specific antibody binding. Myelination in the brain increases with age, so it is a bigger problem in weanlings than in neonates.

To remove the myelin from our samples, we initially tried using Miltenyi myelin depletion columns. With these columns, brain homogenates are pre-incubated with a myelin-specific antibody and then placed on the myelin depletion columns. Myelin should be retained on the column while cells are able to flow through. We encountered obstacles to the effective use of these columns for preparing samples for flow cytometry. First, the myelin removal columns did not satisfactorily remove non-myelin debris from the samples, which still allowed a high degree of non-specific antibody binding. However, the most challenging problem we faced when using the myelin depletion columns was the apparent loss of certain cell types, including microglia, in LPS-stimulated flow cytometry samples (Fig 2.3). This was observed in repeated experiments using mice of both ages. Representative samples pre-incubated with an antibody for CD11b are shown in Figure 2.3. Similar results were observed using antibodies targeting CD45 and CD80 (data not shown). The left graph shows the level of background fluorescence in an unstained control. In the center graph, CD11b⁺ cells in PBS-treated samples are circled. The right graph shows the reduced number of CD11b⁺ cells observed in LPS-treated samples.

We then tried isolating CNS immune cells using Percoll gradients, and with additional trituration, instead of myelin depletion columns. Percoll gradients are often used to isolate immune cells from other CNS components (Ford et al., 1995; Gelderblom et al., 2009; Mausberg et al., 2009; Peterson et al., 2006). We did not initially use Percoll gradients because we planned to examine both microglial and astrocytic populations. Using a 0/30/70% Percoll gradient, astrocytes primarily fractionate with myelin at the 0/30% interface [(Peterson et al.,
Therefore, these Percoll gradients are not a suitable method for isolating astrocytes for flow cytometric analysis. As discussed in Chapter 2, the fraction at the 30/70% interface is enriched for microglia and other immune populations.

Figure 2.5 shows samples prepared either using myelin depletion columns (left) or Percoll gradients (right). Representative samples from neonatal (top) and weanling (bottom) uninoculated mice are shown. The region where cells are expected to be is circled on the graphs (solid line). Samples purified on myelin depletion columns contained more debris, as evidenced by the large number of events with high side scatter but little forward scatter. We also noted fewer cells in weanling samples (bottom) than neonatal samples (top).

Figure 2.6 compares CD45 and F4/80 staining on untreated cells isolated using either myelin depletion columns (A, C, E) or Percoll gradients (B, D, F). Cell gates for these samples are shown in Figure 2.5. Events within the cell gate of (A) myelin-depleted, or (B) Percoll gradient fractionated, neonatal samples are shown. (C) and (D) show the same samples, except Aqua Live/Dead stain was used to gate specifically on live cells. Comparing (A) with (C) demonstrates that gating specifically on live cells markedly reduced the noise in samples prepared using myelin depletion columns. In contrast, comparing (B) with (D) shows that live cell gating does not greatly change the plots of samples prepared using Percoll gradients. These results suggest that dead cells and debris are more effectively separated from CNS immune cells using Percoll gradients than myelin depletion columns. Similar results were observed in weanling samples (data not shown). A comparison of cells within the live cell gate of (E) myelin-depleted, or (F) Percoll gradient fractionated, weanling samples demonstrated that greater numbers of weanling microglia were isolated when samples were prepared using Percoll gradients.
Microglia are identified as CD45$^{lo}$ F4/80$^{+}$. Collectively, these results suggested that isolation and detection of microglia was improved by the use of Percoll gradients, rather than myelin depletion columns. In further experiments, Percoll gradients were used to isolate CNS immune cells.

While the use of Percoll gradients and trituration improved our isolation of microglia from untreated brain tissue, we still needed to improve recovery of LPS-stimulated CNS immune cells, particularly from weanling tissues. To address this, we tried enzymatically digesting the tissue. There are many published reports of successful preparation of CNS cells for flow cytometry using enzymatic digestion (Ford et al., 1995; Gelderblom et al., 2009; Gottfried-Blackmore et al., 2009; Mausberg et al., 2009). We adapted the protocol of Cardona et al. because it was developed specifically for isolation of microglia for both flow cytometry and RNA analysis (Cardona et al., 2006), which we also planned to do. In this protocol, homogenized brains are incubated with collagenase, dispase and DNase. Collagenase and dispase cleave collagen and fibronectin, respectively, while DNase removes extracellular DNA from lysed cells.

Figure 2.7 demonstrates that enzymatic digestion improved detection of LPS-stimulated CNS immune populations. In this experiment, digested and undigested samples from neonatal and weanling mice, with or without LPS stimulation, were examined. Enzymatic digestion did not markedly alter the detection of neonatal cell populations in untreated mice (A & E). However, in untreated weanling samples, digestion increased the number of microglia detected (C & G, solid line). Surprisingly, without enzymatic digestion, loss of CD45$^{hi}$ cells was not observed in LPS-treated samples (B & D, arrows), as we observed previously (Fig 2.3). The
results of the current experiment suggested that the modifications we previously made, namely
the use of Percoll gradients and trituration, were sufficient to improve recovery of LPS-treated
populations. However, enzymatic digestion led to additional recovery of CD45$^+$ cells in LPS-
treated samples (B & F, D & H, dashed line). Therefore, enzymatic digestion was added to the
protocol for future flow cytometry studies.

Flow cytometry on ex vivo astrocytes

Although CNS immune cell detection was greatly improved by the use of Percoll
gradients, our standard Percoll gradients are not appropriate for recovery of astrocytes for flow
cytometry (discussed previously). Figure 2.8 demonstrates typical staining observed with an
astrocyte-specific GFAP antibody. The sample in this figure is from a PBS-inoculated neonatal
mouse and was prepared using a myelin depletion column. (A) shows staining of CD11b$^+$ cells
in this sample. (B) demonstrates GFAP$^+$ staining. (C) contains antibodies for both GFAP and
CD11b. Since GFAP and CD11b are found on separate populations, there should be no double-
positive staining in (C). No distinct GFAP$^+$ populations are apparent, as there are for CD11b.
Thus, GFAP staining may have been non-specific. Similar results were observed in weanling
mice and in LPS-treated mice.

Since isolation of CNS immune cells improved when we used a Percoll gradient instead
of a myelin depletion column, we attempted to modify our standard Percoll gradient in order to
separate astrocytes from myelin. We tried a 0/15/70% gradient, hoping that myelin would stay
at 0/15% interface and all cells would be at 15/70% interface. Unfortunately, this did not work
(data not shown). We next tried a 0/20/30/70% Percoll gradient. In this gradient myelin was
found at both the 0/20% and 20/30% interfaces (data not shown). In summary, we were not able to find a satisfactory method to separate myelin and debris from GFAP\(^+\) astrocyte populations \textit{ex vivo}. Therefore, we limited our \textit{ex vivo} flow cytometry analyses to CNS immune cell populations that could be effectively separated from debris through fractionation at the 30/70% interface of Percoll gradients.

### Discussion

We were initially puzzled by the poor detection of CNS immune populations. However, through a number of modifications to our protocol, we were able to substantially recover these populations. The use of Percoll gradients and trituration led to recovery of microglia and a subset of CD45\(^{\text{hi}}\) immune cells. One reason these cells may have been so challenging to recover is that they are extremely sticky, particularly when activated. They easily bind to one another or are lost during sample preparation through binding to the sides of tubes. The difficulties we initially had may have been due to these cells being non-specifically retained on the myelin depletion columns, a problem that was circumvented by the use of Percoll gradients. The additional trituration may have also assisted in the generation of detectable single cell suspensions.

Microglia are the largest immune population in the brain, so we were quite surprised when enzymatic digestion revealed large populations of CD45\(^{\text{hi}}\) cells in LPS-treated tissues. Immune stimulation readily recruits peripheral immune populations into perivascular spaces within the blood brain barrier (BBB), although their ability to enter the brain parenchyma is much more limited (Bechmann et al., 2007; Ransohoff and Cardona, 2010). Therefore,
enzymatic digestion may be required to sufficiently dissociate the BBB and recover cells within this space. In support of this, Dick et al. demonstrated that dissection of the meninges, choroid plexus and ventricles away from the rest of the brain tissue reduced the number of CD45<sup>hi</sup> cells detected in the brain by five-fold (Dick et al., 1995).

In summary, we have optimized a protocol for the efficient isolation of CNS immune populations under both homeostatic and inflammatory conditions. Unfortunately, we were unable to detect astrocytic populations without concomitant non-specific binding to myelin and other debris.
Figure 2.1 Determination of LPS dosage for intracerebral inoculation of neonatal mice.

Newborn mice were inoculated IC with 0.25, 0.5 or 1 µg LPS per gram of body weight. (A) The highest dosage was fatal for nearly half the mice. n=8-9 per group. (B) Cytokine responses in whole brain tissue were measured in a multiplex bead assay at 12 hpi. Representative cytokines are shown here. n=3-8 per group.
Figure 2.2 Cytokine responses differ with age and TLR agonist. IL-6 and CCL2 levels were measured in 2, 10, 21 and 42 day old brain tissue after IC inoculation with LPS or CpG. Protein concentrations were measured by ELISA and were calculated from in-plate standard curves generated with standards provided by manufacturer. n = 4 mice per group. Data are presented as mean +/- SD. # indicates treatment group contains samples above the dynamic range (based on standard curve). Statistical analysis was completed by two-way analysis of variance with Tukey’s multiple comparisons test. Significant age-specific differences are as indicated:

*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
Figure 2.3 LPS-stimulated cells isolated using myelin depletion columns are poorly detected by flow cytometry. CD11b (AF700) staining is plotted against forward scatter for an unstained control, PBS- and LPS-treated neonatal samples. Positive CD11b staining is circled in PBS- and LPS-treated samples.
Figure 2.4 Enrichment of astrocytic and microglial populations in separate Percoll gradient fractions. Whole brain homogenates were layered over 0/30/70% Percoll gradients. After centrifugation, mRNA expression in the cellular fractions at the 0/30% and the 30/70% interfaces was analyzed by qRT-PCR. (A) Expression of the astrocytic marker Gfap is detected predominantly in the fraction at the 0/30% Percoll interface. (B) Expression of the microglial marker F4/80 is detected predominantly in the fraction at the 30/70% Percoll interface. Data are presented as mean +/- SD. n = 4-5 per group.
Figure 2.5 Comparison of cell populations isolated using myelin depletion columns or Percoll gradients. Cell density plots of forward scatter versus side scatter are shown for neonatal (top) and weanling (bottom) samples. Samples were prepared for flow cytometry either using myelin depletion columns (left) or Percoll gradients (right). Only the 30/70% fraction of the Percoll gradient, which is enriched for CNS immune cells, is shown. Cell population is outlined (not actual cell gate).
Figure 2.6 Comparison of CNS immune populations isolated using myelin depletion columns and Percoll gradients. Different sample preparation methods were compared using untreated neonatal (A-D) and weanling (E-F) brain tissue. Cell density plots of samples stained for the immune marker CD45 and the myeloid marker F4/80 are shown. (A & B) show events within the cell gate, while samples in (C – F) have been gated on both for events within the cell gate and for live cells. Cells were incubated with Aqua Live/Dead stain prior to fixation.
Figure 2.7 Enzymatic digest improves detection of LPS-stimulated CNS immune cells.

Detection of CNS immune populations was compared after preparation of samples without (A – D) and with (E – H) enzymatic digestion (Collagenase D, Dispase I and DNase I) prior to Percoll gradient fractionation. Cell density plots of samples stained for the immune marker CD45 and the myeloid marker F4/80 are shown. Arrows indicate improved detection of LPS-stimulated immune populations, even in the absence of enzymatic digestion. Dashed line circles show even greater detection of LPS-stimulated CD45<sup>hi</sup> populations after enzymatic digestion.
**Figure 2.8 Flow cytometry of astrocytes ex vivo.** Staining for the myeloid cell marker CD11b and the astrocyte cell marker GFAP in a neonatal PBS-treated sample is shown. These markers are not expected to exist on the same cell population in the brain, so double positive staining is not expected. (A) Sample is stained with antibody for CD11b only. (B) Sample is stained with antibody for GFAP only. (C) Sample includes antibodies for both GFAP and CD11b.
CHAPTER THREE

AGE-ASSOCIATED CHANGES IN THE ACUTE NEUROINFLAMMATORY RESPONSE TO TLR4 AND TLR9 STIMULATION IN YOUNG MICE

Introduction

During the perinatal period, the mammalian brain is developing rapidly and is particularly sensitive to inflammation. Gestational viral, bacterial and parasitic infections have been linked to neurological illnesses in offspring, including cerebral palsy, autism and schizophrenia (Brown et al., 2005; Mednick et al., 1988; Nelson and Willoughby, 2000; Shi et al., 2003; Sorensen et al., 2009). Additionally, perinatal infection may increase the risk of developing neurodegenerative diseases such as Alzheimer’s and Parkinson’s later in life (Chen et al., 2011; Ling et al., 2006). Current research suggests that it is not the infectious agent per se but the immune response that may cause neurological damage (Meyer and Feldon, 2010).

Animal models of neurodevelopmental illnesses have demonstrated that perinatal immune stimulation with either infectious agents or Toll-like receptor (TLR) ligands can produce developmental and behavioral changes similar to those observed in human neurological illnesses, including alterations in learning and memory (Gilmore and Jarskog, 1997; Meyer et al., 2009). Moreover, the broad range of infectious organisms associated with neurodevelopmental dysfunction implies the etiology is not restricted to a specific organism. The fact that many immune molecules and cells have additional functions in neurological development also places unique demands on the neonatal immune system (Rolls et al., 2007; Rutkowski et al., 2010; Schafer et al., 2012; Ziv et al., 2006). Therefore, aberrant development
may be both an outcome of the immune system acting on the nervous system and a result of altered functionality within the nervous system.

A factor in how or whether perinatal infection leads to developmental abnormalities is the gestational age when insult occurs (Carvey, 2003; Meyer et al., 2006; Weinstock, 2008). For example, fetal rats exposed to LPS demonstrate progressive dopaminergic neuron loss throughout life only when exposure occurs between embryonic days 10.5 and 11.5 (Carvey, 2003; Ling et al., 2006). While the gestational period is a particularly sensitive time for neurodevelopment, it is not known for how long after birth this sensitivity persists. The exact relationship between age, immune response and specific developmental symptoms is not clear for many situations (Meyer and Feldon, 2010). However, the murine immune response to neurological infection develops dramatically during the first weeks of life, with two to three week old rodents being less susceptible to infection than neonates (Couderc et al., 2008; Ryman et al., 2007; Trgovcich et al., 1999).

In terms of cortical development, a newborn mouse or rat roughly corresponds to a human fetus midway through gestation (Clancy et al., 2001; Clancy et al., 2007a; Clancy et al., 2007b). Therefore, early postnatal immune activation in mice serves as a model to study the impact of infections corresponding with the mid to late gestational period in humans (Bonthius and Perlman, 2007; Hornig et al., 1999; Tohmi et al., 2007).

Many, if not all, cell populations in the brain can produce inflammatory mediators such as cytokines. As discussed in Chapter 1, both microglia and astrocytes regulate the neuroinflammatory response through production of pro- and anti-inflammatory mediators. Moreover, both microglia and astrocytes have developmental functions in the CNS [Chapter 1
Perinatal immune stimulation is thought to increase the risk of neurological illness by over-activating sensitive neonatal microglia ([Bilbo and Schwarz, 2009] and Chapter 1). However, the developmental functions of astrocytes may also require neonatal astrocytes to exist in a heightened activation state under basal conditions. In addition, and as discussed in the introduction (Chapter 1), age-specific differences in inflammatory responses have been noted in peripheral immune populations stimulated with TLR ligands (Belderbos et al., 2009; Chelvarajan et al., 2007; Ferret-Bernard et al.; Nguyen et al., 2010). Therefore, microglia, as well as astrocytes and infiltrating peripheral immune populations, may contribute to age-associated differences in the inflammatory response in the CNS.

Here we have compared neuroinflammation in neonatal and weanling mice by inoculating them with lipopolysaccharide (LPS) or CpG oligonucleotides (CpG), ligands of TLRs 4 and 9, respectively. We measured production of pro- and anti-inflammatory mediators in brain tissue. To better understand the processes leading to heightened neonatal inflammation, we also analyzed usage of common signaling pathways and activation of CNS immune-reactive cell populations.

Results

Neonatal cytokine responses to TLR4 stimulation are heightened and sustained

To characterize how the cytokine response changes during the first weeks of life, we examined cytokine production in neonatal (2 day old) and weanling (21 day old) C57Bl/10 mice after intracerebral (IC) inoculation with LPS or CpG. Control mice were either uninoculated or
inoculated IC with PBS. LPS was used at a concentration of 0.5 µg LPS per gram of body weight, based on the average mouse weight at each age. CpG was used at a concentration of 0.125 µg CpG (40 picomoles) per gram of body weight. These concentrations of LPS and CpG elicit strong neonatal cytokine responses (Fig 3.1 and Fig 3.2) but are not fatal (Fig 2.1 and data not shown).

We characterized the cytokine response using a multiplex bead assay, which is an antibody-based assay that simultaneously measures the protein levels of twenty common cytokines and growth factors. Cytokine levels were calculated using in-plate standards provided by the manufacturer. In response to intracerebral TLR9 stimulation, measured cytokine protein levels were high at 12 hpi but low or undetectable at 24, 48, 72 and 96 hpi [(Butchi et al., 2011) and data not shown]. Similarly, for detectable cytokines, IC TLR4 stimulation led to strong cytokine production at 12 hpi but cytokine levels were low to undetectable at 48 and 96 hpi (data not shown). Therefore, we compared cytokine protein levels at 12 hpi. We focused on the 13 cytokines in the multiplex bead assay that were detectable in brain tissue. In response to LPS, production of the inflammatory cytokines IL-1α, IL-1β, IL-2, IL-5, IL-6, TNF, CXCL9, CCL2 and CCL3 was significantly higher in neonatal brain tissue than in weanling brain tissue (Fig 3.1A). In response to CpG, IL-2, IL-5, TNF, CXCL9 and CCL2 production was elevated in neonatal brains, when compared with weanling brains. In order to confirm our results by an additional method, IL-6 and CCL2 protein levels in neonatal and weanling brains were examined by ELISA (Fig 3.1B). The ELISA findings agreed with trends observed in our multiplex data.

Not all cytokines were up-regulated to higher levels in neonates, when compared with weanling mice. Inflammatory cytokines whose protein levels did not show a statistically
significant age-dependent difference after TLR4 or TLR9 stimulation included IL-12, CXCL1 and CXCL10 (Fig 3.2). However, CXCL10 expression shows the same trend in age-dependent differences that was observed for the cytokines in Figure 3.1. Since several neonatal LPS- and CpG-treated samples were above the standard curve for CXCL10, whether or not age-dependent differences in CXCL10 expression occur cannot be conclusively determined from these data. In addition, significant age-dependent differences in the CpG response were not observed for IL-1α, IL-1β, IL-6 or CCL3. Production of the anti-inflammatory cytokine IL-10 also did not vary significantly with age (Fig 3.2). The multiplex bead assay also tested for IL-4, IL-13, IL-17, IFNγ and GM-CSF, but they were not present at detectable levels at either age. In conclusion, these results indicate that TLR stimulation can provoke elevated cytokine responses in the neonatal CNS. The cytokine response in neonates is further summarized in Table 3.1.

Since the prion protein, PrP<sup>C</sup>, is developmentally expressed in the brain and may play a role in immune cell activation, we also examined cytokine production in neonatal and weanling C57Bl/10 PrP<sup>−/−</sup> mice. Although PrP<sup>C</sup> knock out did not lead to detectable changes in the neuroimmune response (see Chapter 4), similar age-dependent differences in cytokine production were observed in both wild-type and PrP<sup>−/−</sup> mice, including age-dependent differences in IL-6, CCL2 and CXCL9 (compare Fig 4.3 with 4.4).

We considered the possibility that the age-associated differences in the cytokine response reflected differences in timing, rather than the magnitude of the cytokine response (Ortega et al., 2011). To examine this, we looked at mRNA expression levels from 2 to 48 hpi after treatment with either PBS or LPS. Significant differences in Ccl2, Ccl3 and Ifn b1 mRNA levels in PBS-treated neonatal and weanling brains were observed at 2 hpi but not at other time...
points. Age significantly influenced LPS-induced mRNA expression of Il6, Ccl2, Ccl3 and Ifn b1 (Fig 3.3). At 2 hpi after stimulation with LPS, Ccl2 and Il6 levels were comparable between the two ages. By 6 hpi, the LPS response in weanling mice had dropped nearly to basal levels while neonatal Il6 and Ccl2 levels remained high. In contrast, Ifn b1 levels were higher in neonates at 2 hpi but had returned to basal levels in mice of both ages by 6 hpi. Ccl3 mRNA levels were significantly higher in neonates than weanling mice for the duration of the response (Fig 3.3).

In summary, we observed that some cytokine mRNA levels were both prolonged and heightened in neonates in response to immune stimulation.

Age-dependent differences in expression of inflammatory signaling markers

We noted that basal Tlr mRNA levels in the brain and spleen increase with age (Fig 4.2), which contrasts with the age-associated difference in ability to respond to TLR stimulation (Fig 3.1 & Fig 3.3). To examine whether the heightened neonatal cytokine response was a global response, we looked at gene expression in 18 common signaling pathways, including pathways involved in inflammation, survival and development, using a Signal Transduction Pathway Finder SuperArray. Neonatal and weanling brain samples from PBS- and LPS-treated mice were assessed at 6 hpi. Among genes whose expression was altered at least two fold in response to LPS, differences were considered to be age-associated if the LPS-stimulated response between neonates and weanlings was statistically significant and at least two fold different. A minimum difference of two fold was required because each PCR cycle amplifies samples two fold, therefore this is the limit of resolution for PCR. Genes whose expression met these criteria are graphed in Fig 3.4. LPS-stimulated expression of the pro-inflammatory genes Icam1, Nos2,
Cxcl9 and Ccl2 was significantly higher in neonates than weanling mice (Fig 3.4). We also noticed a trend in increased neonatal expression of Birc3, Nfkbia, Il1a, TNF and Irf1 in response to LPS, although these age-associated differences were less than two-fold (data not shown). Collectively, our SuperArray gene expression analysis suggested differential age-associated regulation of the NFκB signaling pathway, which promotes inflammatory signaling downstream of TLR stimulation (Ostuni et al., 2010).

In contrast with the elevated expression of some inflammatory markers in neonates, Bmp4 and Csf2 levels were higher in weanling mice after stimulation with LPS (Fig 3.4). Bmp4, a signaling molecule critical for the development of many organs (Czyz and Wobus, 2001; Hamilton and Anderson, 2004; Ishibashi et al., 2005), was significantly down-regulated in neonatal, but not weanling, brains in response to LPS (p=0.0495). Csf2, a cytokine that promotes the differentiation of granulocytes, monocytes and dendritic cells (Hamilton and Anderson, 2004; Hesske et al., 2010), was induced in weanling, but not neonatal, brains in response to LPS.

Glia contribute to the heightened neonatal response to TLR4 and TLR9 stimulation

To investigate which cell types contribute to the heightened neonatal inflammatory response, we compared mRNA expression levels of glial markers in brain tissue from 2 to 48 hpi (Fig 3.5A-D). mRNA levels of the astrocytic activation marker Gfap were greater in weanling brain tissue at 48 hpi (Figure 3.5A). The activation marker Cd80 is expressed by myeloid cells, including microglia, in the CNS (Hesske et al., 2010; Mausberg et al., 2009; Zhang et al., 2002). Cd80 was significantly heightened in LPS-treated neonatal brains, when compared with
weanling brains, at 12 hpi (Figure 3.5B). In addition, mRNA levels of Slamf7, whose expression we have found primarily in microglia in the CNS (Fig 3.10), were significantly higher in neonates at 6 and 12 hours after LPS inoculation (Fig 3.5C). In contrast, expression of the myeloid marker F4/80 expression increased in parallel in mice of both ages at 48 hours after LPS inoculation (Fig 3.5D) (Lin et al., 2005; Lin et al., 2010).

We also considered whether a peripheral immune cell type, recruited into the brain early in the inflammatory response, could contribute to the acute neonatal response. We examined mRNA levels of the T cell markers Cd3 and Cd8, the dendritic cell (DC) marker Itgax, and the neutrophil marker Ela2. We did not observe a significant increase in expression of any of these markers until 48 hpi (Fig 3.5E-H). Neonatal Ela2 expression was slightly elevated at 12 hpi but strongly induced at 48 hpi (Fig 3.5H). In contrast, Itgax levels were higher, and relatively stable, in neonates from 2 to 12 hpi. However, by 48 hpi, Itgax levels were much higher in weanling mice in response to LPS (Figure 3.5G). Both PBS- and LPS-stimulated levels of the pan T cell marker Cd3 were significantly higher at 48 hpi in neonatal mice (Figure 3.5E). However, Cd8, which is expressed by CD8+ T cells and NKT cells, was similarly induced in mice of both ages (Fig 3.5F). Collectively, the only cell markers that differed at early time points after LPS stimulation were Cd80 and Slamf7. Since both markers are expressed by microglia, these cells may contribute to the heightened inflammatory response in neonates.

To better assess which cell types are contributing to heightened neonatal inflammation, we separated brain tissue into two populations using a 0/30/70% Percoll gradient. After centrifugation, astrocytes, a cell type known to respond to TLR stimulation (Butchi et al., 2010), are predominantly found in the 0/30% fraction [(Butchi et al., 2011) & (Fig 2.4)]. The 30/70%
fraction contains myeloid cells, including microglia and macrophages, and infiltrating immune
cells (Peterson et al., 2006). The immune response cannot be quantitatively compared
between the two fractions because the individual cell types that make up each fraction are
quite different.

Although basal *Tlr4* expression in whole brain tissue increases with age (Fig 3.2), we did
not observe any significant age-dependent changes in *Tlr4* mRNA levels in gradient fractions
enriched for either microglia or astrocytes (Fig 3.6A). Higher overall *Tlr4* mRNA levels were
found in the 30/70% fraction, when compared with the 0/30% fraction, and were strongly
down-regulated in the 30/70% fraction in response to LPS. *Tlr9* mRNA, which was also found
primarily in the 30/70% fraction, increased significantly in this fraction with age (Fig 3.6B). We
examined *Il6* and *Ccl2* mRNA levels in these fractions because we previously observed age-
dependent expression of these genes and their encoded proteins (Fig 3.1 & Fig 3.3). We also
examined mRNA expression of *Nos2* and *Icam1* in these fractions because we found them to be
expressed at higher levels in neonates in whole brain homogenates (Fig 3.4). Although
populations in both fractions contributed to heightened neonatal expression of these genes (Fig
3.6C-F), we observed trends towards higher IL-6 and CCL2 expression in the 30/70% fraction but
higher *Nos2* and *Icam1* expression in the 0/30% fraction.

**Age-associated expression of microglial activating and inhibitory proteins**

To better understand the microglial contribution to neuroinflammation, we assessed
expression of microglial activating and inhibitory proteins in neonatal and weanling brains at 6
hpi. We chose the 6 hour time point because this is when production of many cytokine mRNAs
peak in neonates. We sought to correlate the microglial activation profile with cytokine production. After IC inoculation with PBS or LPS, brain tissue was harvested, and then cells within the 30/70% fraction of Percoll gradients were analyzed by flow cytometry. Representative samples are shown in Figure 3.7. Plots of forward scatter (FSC-A) versus side scatter (SSC-A) were initially used to set cell gates that excluded dead cells and debris (Fig 3.7A-D). Weanling cells consistently had lower side scatter than neonatal cells. Since side scatter is a measure of granularity, and active cells are more granular, this may be due to an increased activity level in neonatal CNS myeloid cells. Distinct cell populations were initially visualized and gated on based on their expression of the leukocyte common antigen CD45 and the myeloid-specific marker F4/80 (Fig 3.7E-H) (Irie-Sasaki et al., 2001; Lin et al., 2010). Microglia are known to express lower levels of CD45 than macrophages, as well as some other immune cell populations, and so were identified as CD45<sup>lo</sup> F4/80<sup>+</sup> (solid line in Fig 3.7E-H) (Ford et al., 1995; Sedgwick et al., 1991). Different cell gates were required for neonatal and weanling microglia because neonatal microglia expressed higher levels of CD45 and F4/80. Macrophages were identified as CD45<sup>hi</sup> F4/80<sup>+</sup> (dotted line in Fig 3.7E-H). Additional cells with CD45<sup>hi</sup> staining and little to no F4/80 expression (F4/80<sup>lo</sup>) were also observed (dashed line in Fig 3.7E-H).

Neonatal samples tended to contain larger amounts of CD45<sup>−</sup> F4/80<sup>−</sup> cells and had more intense staining in the F4/80 (APC) channel (double solid line in Fig 3.7E-H).

We examined expression of the cell surface proteins CD11b, CD11a, CD86, CD172a, CD200R, LY6C and SLAMF7 on CD45 high and low populations (Figures 3.8 & 3.9). CD11a, CD11b and CD86 are activation markers (Kettenmann et al., 2011; Kurpius et al., 2006; Liu et al., 2008). In contrast, CD172a and CD200R inhibit activation (Gitik et al., 2011; Hernangómez et
al., 2012; Liu et al., 2008; Masocha, 2009). SLAMF7 can act either as an activating or inhibitory receptor, depending on the adaptor molecules present (Cruz-Munoz et al., 2009). LY6C expression can help distinguish between different myeloid cell populations (Auffray et al., 2007; Geissmann et al., 2003; Jutila et al., 1994).

In Figure 3.8, populations were color-coded to illustrate age-associated differences CD11b and LY6C expression, as well as in side scatter and forward scatter, which is a measure of size. In Figure 3.8, cells within the microglial gate (solid line in Fig 3.7E-H) are blue, macrophages (dotted line in Fig 3.7E-H) are green, and CD45$^{hi}$F4/80$^{lo}$ cells (dashed line in Fig 3.7E-H) are pink and aqua. CD45$^{-}$F4/80$^{-}$ cells are yellow (double solid line in Fig 3.7E-H). The phenotypes of these cell populations are summarized in Table 3.2. When cells were plotted based on CD45 and CD11b expression, the CD45$^{hi}$F4/80$^{lo}$ cells could be separated into two distinct populations with CD11b high and low expression, which segregated to either side of the macrophage population (Fig 3.8 B & F). The CD45$^{hi}$F4/80$^{lo}$CD11b$^{hi}$ cells are pink while the CD45$^{hi}$F4/80$^{lo}$CD11b$^{lo}$ cells are aqua. In the CD45$^{hi}$F4/80$^{lo}$ population, CD11b expression also correlated with LY6C expression (Fig 3.8 D & H). Examination of F4/80 expression on CD45$^{hi}$ F4/80$^{lo}$ cells in which the CD11b$^{hi}$ and CD11b$^{lo}$ populations were separately colored demonstrated that both of these populations had variable F4/80 expression (Fig 3.8 C & G). Macrophages expressed an intermediate amount of CD11b, high levels of LY6C, and were larger and of intermediate granularity (Fig 3.8 A & E). Microglia were similar to the CD45$^{hi}$F4/80$^{lo}$ CD11b$^{lo}$ cells in their size, granularity, and expression of CD11b and LY6C (Fig 3.8). CD45$^{hi}$ F4/80$^{lo}$CD11b$^{hi}$ cells were the least uniform in size and granularity. Neonatal samples
contained fewer macrophages and CD45<sup>hi</sup> F4/80<sup>lo</sup> CD11b<sup>lo</sup> cells, but more CD45<sup>-</sup> F4/80<sup>-</sup> cells, than weanling samples.

In neonatal PBS-treated samples, we also observed a population of cells with very high forward and side scatter (Fig 3.8 A, dashed red line). Gating on this population shows an additional population of cells in graphs of antibody staining (CD45, F4/80, CD11b, LY6C) that are always to the upper right of the CD45<sup>hi</sup> F4/80<sup>lo</sup> CD11b<sup>lo</sup> population (pink) for all antibodies (data not shown), indicating proportionally higher staining for these antibodies. These cells could be doublets or an additional, uncharacterized population.

Based on the greater overall responsiveness of neonates to neuroinflammatory stimuli, we expected to observe increased expression of activation markers and decreased expression of inhibitory receptors on neonatal microglia in response to LPS, when compared with weanling microglia. Indeed, expression of the activation markers CD11a and CD11b was consistently higher on neonatal microglia when compared with weanling microglia (Fig 3.9 A-C).

Unexpectedly, expression of the inhibitory receptor CD172a was also higher on neonatal microglia than weanling microglia. In addition, these microglial protein levels did not significantly change in response to LPS in mice of either age (Fig 3.9 D-F), possibly due to the early time point post-treatment (6 hpi). Significant age-dependent differences in levels of the activation marker CD86 and in inhibitory CD200R were not observed in microglia (data not shown).

SLAMF7 has been shown to be expressed by a variety of peripheral immune populations (Beyer et al., 2012; Cruz-Munoz et al., 2009; Llinas et al., 2011). However, SLAMF7 expression on microglia has not previously been described. After observing elevated Slamf7 expression in
neonatal whole brain homogenates in response to LPS (Fig 3.5C), we examined *Slamf7* expression in the 0/30% and 30/70% fractions of centrifuged neonatal and weanling Percoll gradients (Fig 3.10A). In response to LPS stimulation, *Slamf7* was primarily up-regulated in the neonatal 30/70% fraction. *Slamf7* expression was also up-regulated in the weanling 30/70% fraction in response to stimulation with CpG. We looked at SLAMF7 expression on CD45+ populations (Fig 3.10B) and found that SLAMF7 protein levels were higher on neonatal microglia than on all other populations examined (p < 0.0001), although it was not elevated following LPS stimulation.

Collectively, our flow cytometry data suggest there may be differences in the ratios of CD45$^\text{hi}$ populations in neonatal and weanling brains, based on expression of CD11b and LY6C. This difference could contribute to the differing cytokine responses observed at each age. Our data also suggest that there are age-associated differences in expression of CD11a, CD11b, CD172a and SLAMF7 on microglia.

We also examined expression of CD11b and CD45 in the spleen. The spleen serves as the primary reservoir for monocytes (Swirski et al., 2009). In response to immune stimulation, splenic monocytes migrate into tissues and differentiate into macrophages and dendritic cells (Geissmann et al., 2010; Swirski et al., 2009). Although we did not observe LPS-specific differences in the CNS at 6 hpi by flow cytometry, CD11b was up-regulated in the spleen in an LPS-dependent manner at this time point (Fig 3.11). In addition, CD45 expression was up-regulated on LPS-stimulated CD11b$^+$ spleen cells. This suggests that the peripheral immune response to TLR4 agonist inoculation in the brain is detectable at least as early as 6 hpi. There were no age-dependent differences in splenic CD11b or CD45 expression.
Discussion

The immune response at birth is immature and infants are often unable to mount an effective response to infection (Levy, 2007). Therefore, we were initially surprised to find that some cytokine levels were higher in neonatal brains than weanling brains in response to TLR4 and TLR9 stimulation. However, as detailed in Chapter 1, recent studies in peripheral tissues and immune cells have demonstrated that age-associated differences in cytokine production can also differ based upon the cell or tissue type being examined (Aksoy, 2006; Chelvarajan et al., 2007; Chelvarajan et al., 2004; Ferret-Bernard et al.; Islam et al., 2012b). In addition, the immune response is uniquely regulated in the brain (Carson et al., 2006; Ransohoff and Cardona, 2010). Therefore, conclusions about the neonatal TLR response in the brain cannot be inferred from studies of other tissues.

Our results extend current knowledge of the neonatal neuroinflammatory response by directly comparing the responses of neonatal and weanling mice to TLR4 or TLR9 stimulation. We demonstrate that production of many cytokines is higher in neonatal brains than in weanling brains. TLR4 stimulation in neonates leads to elevated production of cytokines that are an important part of the inflammatory response in many neurological conditions, including the cytokines IL-1β, TNF and IL-6. TLR9 stimulation also led to increased neonatal cytokine expression, albeit for a smaller subset of cytokines. Our research suggests some cytokine responses to TLR stimulation in the brain are elevated in neonates. This includes higher neonatal levels of IL-1b, TNF and Cxcl9, cytokines whose expression is often inhibited during the neonatal TLR response in the periphery (Angelone et al., 2006; Chelvarajan et al., 2004; Islam et
al., 2012a; Levy et al., 2006a; Nguyen et al., 2010). In contrast, we were unable to detect significantly higher neonatal levels of IL-10, an anti-inflammatory cytokine whose production is often elevated in neonatal peripheral immune cells (Chelvarajan et al., 2007; Ferret-Bernard et al.; Martino et al., 2012). IL-12, which is often expressed at reduced levels in neonatal responses to TLR stimulation in the periphery (Belderbos et al., 2009; Chelvarajan et al., 2004; Islam et al., 2012a), did not differ significantly with age in the brain. Thus, the neonatal response in brain tissue appears to differ from that reported for peripheral tissues.

Although elevated levels of IL-6, IL-1β and TNF in the neonatal brain have been correlated with later cognitive disability and behavioral changes (Bilbo and Schwarz, 2009), few published studies directly compare the neuroinflammatory response of neonates with that of older animals. Ortega et al. recently examined cytokine responses in the brains of neonatal and weanling rats to intraperitoneal LPS administration (Ortega et al., 2011). They found that mRNA levels of Il-6, Il-1β and Tnf peak at 2-6 hpi in weanling brains, but peak at 6-24 hpi in neonatal brains. In contrast, we did not find that cytokine mRNA expression in response to IC LPS occurred sooner in weanling mice. However, we did observe that for the cytokine mRNAs examined, expression was prolonged in neonatal mice. Therefore, whether age-dependent differences in the timing of the CNS cytokine response occur may be influenced by either the location or the trafficking of the immune stimulus in the body.

As described in Chapter 1, altered activation and expression of molecules involved in TLR signaling has been implicated in distinct neonatal immune responses in the periphery (Levy, 2007). In parallel with this, we noted heightened CD11b levels on neonatal microglia when compared with weanling microglia. CD11b is thought to be involved in TLR4 signaling by aiding
the recruitment of intracellular TLR signaling adaptor proteins to lipid rafts, where LPS-bound
TLR4 is localized (Chapter 1). Therefore, elevated microglial CD11b levels could promote
neonatal TLR4 signaling.

In addition to increased microglial CD11b protein levels, CD11a protein levels on
microglia and CD11c (Itgax) mRNA levels in whole brain tissue were also increased in neonates.
CD11a, CD11b and CD11c belong to the β2-integrin family of adhesion molecules. Increased
neonatal expression of β2-integrins supports the theory that neonatal microglia exist in a
heightened activation state because β2-integrins are involved in migration and phagocytosis (Hu
et al., 2010; Liu et al., 2008). Our observations on the age-associated changes in β2-integrin
expression on microglia agree with the morphological studies of others (see Chapter 1) and
suggest that neonatal microglia are in a more active state under basal conditions than microglia
from older animals.

We were initially surprised that CD11a and CD11b levels did not change in response to
TLR4 stimulation. However, we examined the protein levels of microglial activation markers at
the early time point of 6 hpi. In a study of the neonatal microglial response to neuronal
damage, new protein synthesis was not required for early microglial responses, including
migration (Kurpius et al., 2006). This implies that proteins involved in microglial migration, such
as CD11a and CD11b, exist at high enough levels under homeostatic conditions to allow
neonatal microglia to begin to respond to trauma without waiting for new proteins to be
synthesized. While microglial activation in response to other stimuli was not examined, it may
be that new protein synthesis is not required for the early response of neonatal microglial to
LPS. If protein synthesis is not required for the initial changes in microglia associated with
activation, this may explain why we observe age-dependent, but LPS-independent, changes in
microglial activation markers involved in adhesion and migration.

In addition to increased expression of some pro-inflammatory mediators in neonates,
we observed increased expression of the anti-inflammatory mediator CD172a in neonates.
CD172a negatively regulates CD11b-mediated adhesion, migration and phagocytosis (Liu et al.,
2008). Heightened CD172a expression could provide a counterbalance to the elevated levels of
β2-integrins on neonatal microglia.

We found SLAMF7 expression in the brain to be of particular interest because SLAMF7
levels were highest on neonatal microglia. Microglia express lower levels of many immune
receptors than other macrophage populations (Ransohoff and Cardona, 2010). Therefore, it is
somewhat surprising that we detected the highest SLAMF7 expression on neonatal microglia.
SLAMF7 was the only immune cell marker examined in this study whose expression was higher
on microglia than on all other cell populations examined. As mentioned above, SLAMF7 can be
either an activating or inhibitory receptor. The activity of SLAMF7 on microglia is not yet clear.

We observed age-dependent differences in the CNS immune populations found in the
brain. Neonatal samples contained fewer macrophages and CD45\textsuperscript{hi} F4/80\textsuperscript{lo} CD11b\textsuperscript{lo} cells than
weanling samples. The identities of the CD45\textsuperscript{hi} F4/80\textsuperscript{lo} CD11b\textsuperscript{hi} and CD11b\textsuperscript{lo} populations are
unclear. They may include monocytes, as circulating monocytes have been shown to express
lower levels of F4/80 than tissue resident macrophages (Lin et al., 2010). However, the CD45\textsuperscript{hi}
populations could also include T cells, neutrophils and DCs. Other studies have noted small
endogenous populations of dendritic cells, T cells and neutrophils in murine and primate brains
under homeostatic conditions (Bischoff et al., 2011; Dick et al., 1995; Ford et al., 1995;
In addition, intracerebral immune stimulation can lead to a large influx of peripheral immune cells, including DCs (Gelderblom et al., 2009; Hesske et al., 2010; Mausberg et al., 2009).

The number of CD45$^{hi}$ cells detected in LPS-treated samples was reduced when compared with PBS-treated samples. These results were observed in both neonatal and weanling tissues. It is unclear why fewer CD45$^{hi}$ cells were detected in LPS-stimulated samples because immune stimulation is expected to increase recruitment of peripheral immune cells. Montero-Menei et al. reported a similar phenomenon in rats that were either inoculated IC with LPS or received an IC stab lesion (Montero-Menei et al., 1996). At 5 hpi, greater infiltration of CD11b$^+$ cells was observed in the stab lesioned brains than in the LPS inoculated brains. However, at 15 hours and later there was greater CD11b$^+$ infiltration into LPS-treated brains than into stab lesioned brains (Montero-Menei et al., 1996). If IC LPS initially suppresses immune cell recruitment but later promotes it, as suggested by Montero-Menei et al., then LPS-specific recruitment of peripheral immune cells could also be delayed in our model.

In neonatal PBS-treated samples we also observed a population of cells with very high forward and side scatter (dashed red line in Fig. 3.8 A). This population may include doublets, perhaps due to the rapid cell division occurring at this age. Alternatively, this could be a distinct population of cells.

We found that mRNA levels of the astrocyte activation marker Gfap were higher in weanling mice. However, we suspect that, in this situation, Gfap expression does not accurately reflect the activation state of neonatal astrocytes. Gfap is an intermediate filament protein involved in cytoskeletal structure. Gfap levels may more accurately reflect that
weanling astrocytes have more, and larger, processes than neonatal astrocytes. We expect that astrocytes contribute to the elevated inflammatory response observed in neonatal brains because astrocytes are a component of the 0/30% Percoll gradient fraction, which contributes to the elevated neonatal response. Other cells, such as oligodendrocytes or ependymal cells, may also contribute to the inflammatory response observed in the 0/30% fraction.

In addition to shedding light on the etiology of neurodevelopmental disorders, a better understanding of the unique pro- and anti-inflammatory aspects of the neonatal immune response may lead to the development of more effective treatments for the initial infection as well as its long term consequences.
Table 3.1 Age-associated changes in cytokine responses.

<table>
<thead>
<tr>
<th></th>
<th>Overall significant interaction between age and treatment?</th>
<th>Change in response to LPS</th>
<th>Neonatal response to CpG</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-2</td>
<td>Y</td>
<td>↑*</td>
<td>↑*</td>
</tr>
<tr>
<td>IL-5</td>
<td>Y</td>
<td>↑*</td>
<td>↑*</td>
</tr>
<tr>
<td>TNF</td>
<td>Y</td>
<td>↑*</td>
<td>↑*</td>
</tr>
<tr>
<td>CCL2</td>
<td>Y</td>
<td>↑*</td>
<td>↑*</td>
</tr>
<tr>
<td>CXCL9</td>
<td>Y</td>
<td>↑*</td>
<td>↑*</td>
</tr>
<tr>
<td>IL-1a</td>
<td>Y</td>
<td>↑*</td>
<td>↔</td>
</tr>
<tr>
<td>IL-1b</td>
<td>Y</td>
<td>↑*</td>
<td>↔</td>
</tr>
<tr>
<td>IL-6</td>
<td>N</td>
<td>↑*</td>
<td>↔</td>
</tr>
<tr>
<td>CCL3</td>
<td>N</td>
<td>↑*</td>
<td>↔</td>
</tr>
<tr>
<td>IL-10</td>
<td>N</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>IL-12</td>
<td>N</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>CXCL1</td>
<td>N</td>
<td>↔*</td>
<td>↔</td>
</tr>
<tr>
<td>CXCL10</td>
<td>N</td>
<td>↔*</td>
<td>↔*</td>
</tr>
</tbody>
</table>

Overall significant interactions between age and treatment are listed in the first column. Arrows indicate direction of response in neonates when compared with weanling mice. Asterisk indicates whether cytokine was significantly induced in neonates in response to the given agonist. Statistical analysis was completed by two-way analysis of variance with Sidak’s multiple comparisons test.
Table 3.2 Phenotypes of examined cell populations.

<table>
<thead>
<tr>
<th>Population</th>
<th>Color in Figure 3.8</th>
<th>CD45&lt;sup&gt;lo&lt;/sup&gt;</th>
<th>F4/80&lt;sup&gt;+&lt;/sup&gt;</th>
<th>CD11b&lt;sup&gt;lo&lt;/sup&gt;</th>
<th>Ly6C&lt;sup&gt;-&lt;/sup&gt;</th>
<th>SSC&lt;sup&gt;lo&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microglia</td>
<td>Blue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophages</td>
<td>Green</td>
<td>CD45&lt;sup&gt;hi&lt;/sup&gt;</td>
<td>F4/80&lt;sup&gt;+&lt;/sup&gt;</td>
<td>CD11b&lt;sup&gt;int&lt;/sup&gt;</td>
<td>Ly6C&lt;sup&gt;hi&lt;/sup&gt;</td>
<td>SSC&lt;sup&gt;int&lt;/sup&gt;</td>
</tr>
<tr>
<td>Other cell populations:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>Pink</td>
<td>CD45&lt;sup&gt;hi&lt;/sup&gt;</td>
<td>F4/80&lt;sup&gt;lo&lt;/sup&gt;</td>
<td>CD11b&lt;sup&gt;hi&lt;/sup&gt;</td>
<td>Ly6C&lt;sup&gt;hi&lt;/sup&gt;</td>
<td>SSC&lt;sup&gt;hi&lt;/sup&gt;</td>
</tr>
<tr>
<td>Unknown</td>
<td>Aqua</td>
<td>CD45&lt;sup&gt;hi&lt;/sup&gt;</td>
<td>F4/80&lt;sup&gt;lo&lt;/sup&gt;</td>
<td>CD11b&lt;sup&gt;lo&lt;/sup&gt;</td>
<td>Ly6C&lt;sup&gt;-&lt;/sup&gt;</td>
<td>SSC&lt;sup&gt;lo&lt;/sup&gt;</td>
</tr>
<tr>
<td>Unknown</td>
<td>Yellow</td>
<td>CD45&lt;sup&gt;-&lt;/sup&gt;</td>
<td>F4/80&lt;sup&gt;-&lt;/sup&gt;</td>
<td>CD11b&lt;sup&gt;lo&lt;/sup&gt;</td>
<td>Ly6C&lt;sup&gt;-&lt;/sup&gt;</td>
<td>n.d.</td>
</tr>
</tbody>
</table>

n.d. = not determined
Table 3.3 Percentage of cells in examined populations.

<table>
<thead>
<tr>
<th>Color in Figure 3.8</th>
<th>2 d, PBS</th>
<th>2 d, LPS</th>
<th>21 d, PBS</th>
<th>21 d, LPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microglia</td>
<td>Blue</td>
<td>20.1 ± 7.4</td>
<td>43.2 ± 3.7</td>
<td>56.3 ± 7.2</td>
</tr>
<tr>
<td>Macrophages</td>
<td>Green</td>
<td>2.0 ± 0.2</td>
<td>1.8 ± 0.4</td>
<td>13.1 ± 1.5</td>
</tr>
<tr>
<td>Unknown CD11b\textsuperscript{hi}</td>
<td>Pink</td>
<td>58.2 ± 8.9</td>
<td>15.9 ± 0.3</td>
<td>19.6 ± 7.4</td>
</tr>
<tr>
<td>Unknown CD11b\textsuperscript{lo}</td>
<td>Aqua</td>
<td>0.5 ± 0</td>
<td>0.5 ± 0.2</td>
<td>3.6 ± 0.8</td>
</tr>
<tr>
<td>CD45\textsuperscript{−}</td>
<td>Yellow</td>
<td>15.6 ± 0.8</td>
<td>35.6 ± 4.4</td>
<td>3.8 ± 0.7</td>
</tr>
</tbody>
</table>
Figure 3.1 Heightened neonatal cytokine responses to IC TLR4 and TLR9 stimulation. Neonatal (2 d.o.) and weanling (21 d.o.) mice were inoculated intracerebrally (IC) with LPS or CpG. Control groups were either not inoculated or inoculated IC with PBS. (A) Cytokine protein levels
in brain homogenates from neonatal and weanling mice were measured at 12 hpi using a multiplex bead assay. n = 10-12 for 2 d.o. mice and includes the combined results from two independent experiments, n = 5-6 for 21 d.o. mice from one independent experiment. **(B)** Age-dependent differences in cytokine production were confirmed by ELISA for IL-6 and Ccl2. n = 5 mice per group. Data are presented as mean +/- SD. For both assays, protein concentrations were calculated using in-plate standard curves derived from manufacturer-provided protein standards. Dotted line indicates lower limit of detection (based on standard curve). # indicates treatment group contains samples above the dynamic range (based on standard curve). Outliers detected by Grubbs’ test were excluded. Statistical analysis was completed by two-way analysis of variance with Sidak’s multiple comparisons test. Significant age-specific differences are as indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Figure 3.2 Production of some cytokines does not differ with age in response to IC LPS or CpG.

Neonatal and weanling mice were inoculated IC with PBS, LPS or CpG, or remained uninoculated. Cytokine protein levels in whole brain homogenates were measured at 12 hpi using a multiplex bead assay. n = 10-12 for 2 d.o. mice and includes the combined results from two independent experiments, n = 5-6 for 3 w.o. mice from one independent experiment.

Dotted line indicates lower limit of detection (based on standard curve). # indicates treatment group contains samples above the dynamic range (based on standard curve). Outliers detected by Grubbs’ test were excluded. Statistical analysis was completed by two-way analysis of variance and Sidak’s multiple comparisons test. Data are presented as mean +/- SD.
Figure 3.3 Heightened and prolonged inflammatory cytokine responses in neonates. Cytokine mRNA levels in whole brain homogenates from neonatal and weanling mice were assayed at 2, 6, 12 and 48 hpi after IC inoculation with PBS or LPS. n = 4-6 mice per group. No statistically significant differences in Il6 levels were observed between PBS treated neonatal and weanling mice. Neonatal PBS treated mice expressed significantly higher levels of Ccl2, Ccl3 and Ifn β1 than weanling PBS treated mice at 2 hpi only (p=0.0339 for Ccl2, p=0.0143 for Ccl3, p=0.0075 for Ifn β1). Data are presented as mean +/- SE. Statistical analysis was completed by two-way analysis of variance with Tukey’s multiple comparisons test. Significant age-specific differences in the LPS response are indicated in the figure as: **p<0.01, ***p<0.001, ****p<0.0001.
Figure 3.4 Age-associated differences in expression of signaling markers. Age-dependent differences in the LPS response were analyzed using a PCR SuperArray designed to detect differential usage of 18 common signaling pathways, including pathway involved in inflammation, survival and development. mRNA expression levels in whole brain homogenates of neonatal and weanling mice were tested at 6 hpi with PBS or LPS. Data presented here include genes whose expression showed a statistically significant change in response to both LPS and age. \( n = 4 \) mice per group. Data are presented as mean +/- SD. Statistical analysis was completed by two-way analysis of variance with Tukey’s multiple comparisons test. Significant age-specific differences are as indicated: *\( p<0.05 \), **\( p<0.01 \), ***\( p<0.001 \), ****\( p<0.0001 \)
Figure 3.5 Temporal expression of glial and immune cell markers after TLR4 stimulation.

mRNA levels of glial and immune cell markers in whole brain homogenates from neonatal and weanling mice were tested at 2, 6, 12 and 48 hpi with PBS or LPS. (A) mRNA levels of the astrocytic marker *Gfap* are higher in weanling mice. (B) *Cd80*, which is expressed by microglia and macrophages in the CNS, is induced early in the inflammatory response, and to a greater degree, in neonates. (C) *Slamf7*, which is expressed by microglia, is also induced early, and to a greater degree, in neonates. (D) The myeloid marker *F4/80* is not strongly induced until 48 hpi and is not induced in an age-specific manner. (E) Neonatal expression of the pan T cell marker
Cd3 is higher under mock- and LPS-inoculated conditions at 48 hpi. (F) No age-associated
differences were observed for Cd8, which is expressed by a T cell subset and NKT cells. (G) The
dendritic cell marker Itgax is expressed at higher levels in neonates at early time points, but not
significantly more in response to LPS. At 48 hpi, Itgax levels are significantly higher in LPS-
stimulated weanling mice. (H) The neutrophil marker Ela2 is expressed at higher levels in
neonates in response to LPS at 12 and 48 hpi. No statistically significant differences in Cd80,
F4/80, Slamf7, Gfap, Cd8 or Ela2 levels were observed between PBS-treated neonatal and
weanling mice. Cd3 levels were significantly higher in PBS-treated neonates than in weanling
mice at 48 hpi. Itgax levels were significantly higher in neonates in response to PBS at 2, 6 and
12 hpi. n = 4-6 mice per group. Data are presented as mean +/- SE. Statistical analysis was
completed by two-way analysis of variance with Tukey’s multiple comparisons test. Significant
age-specific differences in the LPS response are as indicated: *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001
Figure 3.6 Both astrocyte- and microglia-enriched fractions contribute to heightened neonatal expression of inflammatory genes. At 6 hours after IC inoculation with PBS, LPS, or CpG, brain homogenates from neonatal and weanling mice were fractionated on Percoll gradients, and mRNA expression levels were analyzed by qRT-PCR. (A & B) *Tlr4* and *Tlr9* are predominantly
expressed in the 30/70 % fraction, which is enriched for microglia. (A) Tlr4 levels did not vary
with age. LPS stimulation leads to significant down-regulation of Tlr4 in neonatal and weanling
30/70 % fractions (p<0.0001). A similar trend in Tlr4 down-regulation is observed in the 0/30%
fraction, which is enriched for astrocytes. (B) Under all conditions tested, Tlr9 expression
significantly increases with age in the 30/70 % fraction. (C) Il6 production is significantly higher
in the neonatal 30/70% fraction, when compared with weanling mice. (D) Ccl2 expression is
significantly elevated under all conditions in neonatal 30/70% fractions, as well as the neonatal
0/30% fraction in response to LPS. (E) In response to LPS, iNOS levels are significantly higher in
both neonatal fractions than in weanling fractions. In response to CpG, the 0/30% fraction
expresses significantly higher iNOS mRNA levels in neonates. (F) Icam1 expression is
significantly higher in LPS-stimulated 0/30% fractions. n = 4-5 per group. Data are presented as
mean +/- SD. Statistical analysis was completed by two-way analysis of variance with Tukey’s
multiple comparisons test. Significant age-specific differences in the response to LPS or CpG
are as indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
Figure 3.7 Cell population gates used for analysis by flow cytometry. At 6 hours after inoculation, samples were isolated on Percoll gradients, then analysis of CNS immune cell populations was performed using flow cytometry. (A-D) Side scatter (SSC) and forward scatter (FSC) were used to create cell gates and exclude debris and apoptotic cells (gate shown). Cell populations were separated by their expression of CD45 and F4/80. (E-H) Microglia were identified as CD45$^{lo}$ F4/80$^+$ (solid line). Macrophages were identified as CD45$^{hi}$ F4/80$^+$ (dotted line). Other immune cells were CD45$^{hi}$ F4/80$^{lo}$ (dashed line). Unstained cells were CD45$^-$ F4/80$^-$ (double line). Representative samples are shown. (A & E) 2 d.o., PBS IC; (B & F) 2 d.o., LPS IC; (C & G) 21 d.o., PBS IC; (D & H) 21 d.o., LPS IC. Circles are for illustrative purposes only and are not the actual cell gates.
Figure 3.8 CNS immune cell populations. Cell populations could be further distinguished by their (A & E) side and forward scatter, (B & F) CD11b and (D & H) Ly6C expression. (C & G) F4/80 expression is also shown. (B-D, F-H) For reference, all samples were plotted against CD45 expression on the y-axis. Representative samples from PBS-treated mice are shown. (A-D) Neonatal; (E-H) Weanling. Cell populations are color-coded: CD45<sup>lo</sup> F4/80<sup>+</sup> microglia (blue), CD45<sup>hi</sup> F4/80<sup>+</sup> macrophages (green), CD45<sup>hi</sup> F4/80<sup>lo</sup> immune cells (aqua and pink), CD45<sup>-</sup> F4/80<sup>-</sup> cells (yellow).
Figure 3.9 Increased expression of activating and inhibitory markers on neonatal microglia.

Microglial populations were analyzed ex vivo at 6 hpi after IC PBS or LPS inoculation. Neonatal microglia exhibit increased expression of (A & D) CD11b, (B & E) CD11a and (C & F) CD172a. Histograms in (A-C) show representative PBS-treated neonatal and weanling samples, as well as unstained control. Mean fluorescence intensity (MFI) after PBS or LPS treatment is plotted for each antigen in (D-F). Protein levels differed significantly in an age-dependent, but LPS-independent, manner at this time point. Data was reproduced in an additional experiment that used lower antibody concentrations. n = 2-3 mice per group. Data are presented as mean +/- SD. Statistical analysis was completed by two-way analysis of variance with Tukey’s multiple comparisons test. Significant age-specific differences are as indicated: **p<0.01, ***p<0.001, ****p<0.0001.
Figure 3.10 SLAMF7 is strongly expressed by neonatal microglia. (A) Slamf7 expression in neonatal and weanling Percoll gradient fractions is shown at 6 hours after IC stimulation with PBS, LPS or CpG. Slamf7 was significantly induced in the neonatal 30/70% LPS-stimulated fraction. A similar trend was observed, but to a lesser extent, in the weanling 30/70% CpG-stimulated fraction. Statistical analysis was completed by two-way analysis of variance with Tukey’s multiple comparisons test. n=4-5 per group. (B) SLAMF7 mean fluorescence intensity (MFI) for neonatal and weanling populations separated by CD45 and F4/80 staining (see Figure 3.7). ‘Unknown’ refers to CD45hi population. Expression of SLAMF7 was significantly elevated
in neonatal microglia when compared with other populations shown (p<0.0001). Statistical analysis was completed by two-way analysis of variance with Dunnett’s multiple comparisons test and Tukey’s multiple comparisons test. n=2-3 per group.
Figure 3.11 Increased expression of CD11b in the spleen after IC LPS. Forward scatter and side scatter were used to gate on cells (red line) in the spleen. CD11b expression is shown for representative neonatal and weanling spleen samples after IC treatment with PBS or LPS. CD45 expression is shown for CD11b+ populations only. Splenic CD11b and CD45 expression was analyzed in two independent experiments in weanling mice and one experiment in neonatal mice.
CHAPTER FOUR

PRION PROTEIN AND THE NEUROINFLAMMATORY RESPONSE

TO TOLL-LIKE RECEPTOR 4 AND 9 STIMULATION IN YOUNG MICE

Introduction

PrP\(^c\) is expressed in most tissues but expression is highest in neurons (Bendheim et al., 1992). There are also significant PrP\(^c\) levels in microglia, astrocytes and many peripheral immune cell types (Arantes et al., 2009; Brown et al., 1998; Dodelet and Cashman, 1998; J. D. Isaacs, 2006). PrP\(^c\) is developmentally regulated (Lazarini et al., 1991; Lieberburg, 1987; Manson et al., 1992; Moser et al., 1995) and influences neuronal survival, astrocyte development, and the acute stress response (Arantes et al., 2009; Lima et al., 2007; Nico et al., 2005). However, PrP knock out (PrP\(^{−/−}\)) mice do not exhibit any gross phenotypic abnormalities (Bueler et al., 1992; Manson et al., 1994) and the precise role of PrP\(^c\) remains poorly defined.

PrP\(^c\) expression is differentially regulated in activated immune cells and influences several aspects of immune cell function. PrP\(^c\) expression regulates macrophage phagocytosis and stimulates signaling pathways involved in phagocytosis, cellular migration and cytokine production in vitro (de Almeida et al., 2005; Krebs et al., 2006). Dendritic cell expression of PrP\(^c\) is required for dendritic cell activation of T cells (Ballerini et al., 2006). In vivo, PrP\(^c\) expression alters macrophage phagocytosis and recruitment of immune cells to the site of inflammation in the periphery (de Almeida et al., 2005). Several papers report altered cytokine production in PrP\(^{−/−}\) tissues and cells, including reduced production of TNF in injured PrP\(^{−/−}\) muscles, less IL-2 and IL-4 production by stimulated PrP\(^{−/−}\) splenocytes, and increased IL-6 expression in inflamed PrP\(^{−/−}\) colons (Bainbridge and Walker, 2005; Martin et al., 2011; Stella et al.).
Despite the high expression of PrP⁶ in the central nervous system (CNS) and the influence of PrP⁶ over the immune response, research examining the role of PrP⁶ in the neuroimmune response is limited. In cultured microglia, PrP⁶ expression is proportional to the degree of microglial proliferation and activation, with PrP⁶/- microglia being the least responsive to activation (Brown et al., 1996; Brown et al., 1998; Herms et al., 1997). Nasu-Nishimura et al. reported that PrP⁶/- mice infected with encephalomyocarditis viral (ECMV) display reduced microglial activation and recruitment of peripheral immune cells into the brain when compared with wild-type (WT) mice (Nasu-Nishimura et al., 2008). PrP⁶ exerts a neuroprotective effect in the CNS in response to sterile inflammation caused by ischemia (McLennan et al., 2004; Sakurai-Yamashita et al., 2005).

In the present study, we examined how PrP⁶ influences the neuroinflammatory response in vivo using a model system that activates Toll-like receptor (TLR) signaling pathways. TLRs activate the innate immune system through binding to conserved molecular patterns associated with both infection and sterile inflammation. We chose to use the TLR9 ligand, CpG-rich DNA (CpG), and the TLR4 ligand, lipopolysaccharide (LPS), both of which also bind PrP⁶. PrP⁶ binds nucleic acids with high affinity but low specificity (Cordeiro et al., 2001; Gabus et al., 2001; Weiss et al., 1997). DNA binding leads to conformational changes and aggregation of the prion protein (Cordeiro et al., 2001; Nandi et al., 2002; Yin et al., 2008). Additionally, nucleic acid and phosphorothioated nucleic acid binding to prion protein causes internalization of the PrP:DNA complex while PrP⁶ expression promotes uptake of DNA (Kocisko et al., 2006; Yin et al., 2008). Such molecules can also strongly influence conversion of PrP⁶ to PrP⁶Sc both in vivo and in vitro (Cordeiro et al., 2001; Deleault et al., 2003; Kocisko et al., 2006). LPS binds PrP⁶ under
conditions of normal and low pH (Pasupuleti et al., 2009) and is reported to up-regulate PrP\(^C\) expression in spleens, as well as in macrophage and microglial cell lines (Gilch et al., 2007; Lotscher et al., 2007).

Here, we have tested whether PrP\(^C\) influences cytokine production and glial activation in response to TLR stimulation with LPS or CpG by comparing responses in WT, PrP\(^{-/-}\), and Tg7 mice. In Tg7 mice, mouse prion protein has been knocked out and hamster prion protein, which is similar in sequence, is expressed at three to four fold higher levels than normal. We examined these responses shortly following birth, when mice are undergoing rapid neurological development, and at 21 days, when physiological levels of PrP\(^C\) are higher in the brain.

**Results**

PrP\(^C\) expression in the brain changes with age but not in response to LPS or CpG stimulation

As the PrP\(^{-/-}\) mice that we used had been bred extensively onto the C57Bl/10 background, we used WT C57Bl/10 mice as our PrP\(^C\) positive controls. Tg7 PrP\(^{c}\) overexpressing mice were also on a C57Bl/10 background and overexpress hamster PrP\(^c\), which is similar in sequence to mouse PrP\(^C\). We examined the neuroinflammatory response in neonatal (2 d.o.) and weanling (21 d.o.) mice because the developmental increase in brain Prnp expression leveled off at 21 days of age in C57Bl/6 mice (Lazarini et al., 1991). However, when we later looked at Prnp mRNA levels in WT C57Bl/10 mice from 2 to 42 days of age using quantitative real-time PCR (qRT-PCR), we observed that basal brain Prnp levels continued to rise over the entire time period examined (Fig 4.1A). Although C57Bl/10 Prnp levels increased approximately five-fold in the brain in the first six weeks of life, Prnp levels in the peripheral immune organs of
the spleen and thymus remained constant over this period (Fig 4.1A). We also examined whether TLR4 stimulation influenced PrP^c expression. Prnp mRNA levels in WT mice were monitored by qRT-PCR from 2-48 hpi after TLR4 stimulation in 2 and 21 day old mice (Fig 4.1B).

No significant differences in brain PrP^c mRNA levels were observed in response to TLR 4 stimulation in mice of either age over the time course examined.

**Tlr4 and Tlr9 gene expression is not affected by a lack of PrP^c under homeostatic or inflammatory conditions**

We next tested whether PrP^c influences Tlr mRNA expression. Basal mRNA levels of Tlrs 3, 4, 7, 8 and 9 were examined in the brain, spleen and thymus of WT and PrP^−/− mice at 2, 14 and 42 d.o. (Fig 4.2 A-C). Over the time period examined, mRNA levels of Tlrs 3, 4, 7 and 9 rose four- to six-fold in the brains of both WT and PrP^−/− mice, while Tlr8 levels remained unchanged. Splenic Tlr levels increased two- to five-fold in WT and PrP^−/− mice while thymic Tlr levels were unchanged with age. Lack of PrP^c did not significantly influence basal Tlr expression in any tissue or time point examined. The effect of PrP^−/− on Tlr4 and 9 mRNA levels after TLR stimulation was also examined (Fig 4.2 D & E). We saw no significant differences in brain Tlr4 or Tlr9 mRNA levels between WT and PrP^−/− mice of either age in response to LPS or CpG, nor were agonist-specific alterations in Tlr4 or Tlr9 levels were detected.

Lack of effect of PrP^c expression on cytokine responses to intracerebral TLR4 or TLR9 stimulation
To determine whether PrP$^C$ influences cytokine responses, we treated mice with LPS or CpG by IC inoculation. As controls, mice were either left uninoculated or inoculated with PBS. Cytokine and growth factor protein levels in whole brain homogenates were examined by multiplex bead assay at 12 hpi in WT and PrP$^{-/-}$ neonatal (Fig 4.3) and weanling (Fig 4.4) brain tissue. Although strong inflammatory cytokine induction was observed, no differences in production of the inflammatory cytokines IL-1β, IL-6, IL-12, Cxcl1, Cxcl9, Ccl2 or Ccl3 were detected between WT and PrP$^{-/-}$ brain tissue in 2 or 21 d.o. mice. Additionally, no PrP$^C$-dependent differences were noted for the anti-inflammatory cytokine IL-10. Similar results were observed for the cytokines IL-1α, IL-2, IL-5 and TNF and the growth factors FGF and VEGF (data not shown). IL-4, IL-13, IL-17, IFNγ and GM-CSF were also assayed but were not present at detectable levels under the conditions tested.

Due to limited quantities of mice available in the Tg7 strain, we only examined the cytokine responses to IC PBS or CpG in weanling mice of this strain. Figure 4.5 shows production of IL-1β, IL-12, CCL3, CXCL9 and CXCL10 in Tg7, WT and PrP$^{-/-}$ brains and is representative of the cytokine responses observed in weanling Tg7 mice. PrP$^C$ overexpression in Tg7 mice did not influence cytokine production in the brain.

In previous studies using the IRW mouse strain, some cytokine levels in the brain remained heightened at 48 and 96 hpi after TLR stimulation (Butchi et al., 2008). Therefore, we also examined neonatal brain homogenates at 48 and 96 hpi to determine whether PrP$^C$ influenced late cytokine responses. However, all cytokines had returned to basal levels in C57Bl/10 WT and PrP$^{-/-}$ mice by 48 hpi (data not shown).
PrP$^c$ expression did not influence glial activation

To test for effects of PrP$^c$ on other aspects of glial activation, we assessed induction of glial activation markers by qRT-PCR in neonatal WT and PrP$^{-/-}$ brains (Fig 4.6). We examined mRNA expression of glial activation markers at 6 and 12 hpi after TLR4 or TLR9 stimulation. However, most mRNAs had returned to basal levels by 12 hpi, so only the 6 hour data are shown here. Cd80 is expressed by activated microglia while Nos2, Gpr84 and Icam1 are induced in both microglia and astrocytes in response to neuroinflammation. No significant differences were detected between WT and PrP$^{-/-}$ brains in the mRNA levels of any of the glial activation markers tested.

We also performed histologic analyses of WT and PrP$^{-/-}$ brain sections that were taken at 12, 48 and 96 after inoculation with PBS, LPS, CpG, as well as uninoculated controls. Tissues were stained with hematoxylin and eosin, glial fibrillary acidic protein (GFAP), or ionized calcium binding adaptor molecule 1 (IBA1). No significant differences in inflammation, peripheral immune cell infiltration, astrocytic activation or microglial activation were observed (data not shown).

Discussion

Microglia and astrocytes are the primary immune-responsive cells of the brain and have many overlapping functions, including release of inflammatory and neurotrophic factors and phagocytosis of debris. Prion protein has been demonstrated to influence microglial activation in vitro (Brown et al., 1996; Brown et al., 1998; Herms et al., 1997). Astrocytic PrP$^c$ plays a role in both astrocytic and neuronal development (Arantes et al., 2009; Lima et al., 2007). PrP$^c$ has
not yet been shown to influence the immune-specific functions of astrocytes. We hypothesized that PrP\(^c\) expression would influence the neuroimmune response *in vivo*. However, after measuring several parameters of the neuroinflammatory response, we have not observed any differences between WT, PrP\(^{-}\)/ and PrP\(^c\) overexpressing mice.

The apparent discord between our results and published studies may be because our experiments utilized *in vivo* models while most published studies were restricted to *in vitro* models. Discrepancies between *in vitro* and *in vivo* responses were recently noted by Mariante et al., who observed that TNF up-regulates neutrophil expression of PrP\(^c\) *in vitro* but not *in vivo* (Mariante et al., 2012). This group also noted that neutrophil, but not brain, PrP\(^c\) was up-regulated in response to LPS. Another possibility is that PrP\(^c\) influences the inflammatory response of a specific cell type in wild-type mice but in a manner that is undetectable in PrP\(^{-}\)/ mice due to compensation by another molecule or cell type.

It is possible that purified TLR agonist is not sufficient to stimulate PrP\(^c\)-dependent differences in the neuroinflammatory response. TLR 4 and 9 agonists were chosen because interactions between PrP\(^c\) and nucleic acids are well-documented and PrP\(^c\) has recently also been shown to bind LPS. However, upon intracranial inoculation of mice with ECM virus, Nasu-Nishimura et al. reported that PrP\(^{-}\)/ mice displayed reduced recruitment of peripheral immune cells into the brain and reduced microglial activation when compared with WT cells (Nasu-Nishimura et al., 2008). Since ECM virus infection activates a broader range of immune pattern recognition receptors, it is conceivable that PrP\(^c\)-dependent modulation of the immune system occurs through a mechanism independent of TLR signaling.
The above PrP\textsuperscript{c}-associated differences were only apparent when using 15 week old mice but not in experiments with 6 week old mice (Nasu-Nishimura et al., 2008). Similarly, Keshet et al. found that age influences the activity and subcellular localization of neuronal nitric oxide synthase (nNOS) (Keshet et al., 1999). In 30 day old mice, PrP knock out did not impair nNOS function or localization to lipid rafts. Both localization and enzymatic activity were impaired in 100 day old PrP\textsuperscript{+/−} brains. These results imply that either PrP\textsuperscript{c} influences the neuroinflammatory response only in mature mice, or compensatory mechanisms for mitigating the loss of PrP\textsuperscript{c} decline with age. We did not examine the PrP\textsuperscript{c}-dependent response in mature mice. It is possible that PrP\textsuperscript{c} could influence the TLR response in older mice.

The cellular differentiation state of astrocytes and microglia may influence the function of PrP\textsuperscript{c} within these cell types. Although PrP\textsuperscript{c} is expressed in astrocytes and microglia in young mice, it does not appear to influence the inflammatory response in these cells. PrP\textsuperscript{c} is involved in development of the central nervous system. Conceivably, PrP\textsuperscript{c} in young glial cells could be restricted to developmental functions but in older glial cells takes on immunoregulatory functions.

PrP\textsuperscript{c} and TLR4 share several physiological characteristics. Both PrP\textsuperscript{c} and TLR4 are plasma membrane proteins that migrate into lipid rafts upon ligand binding, which stimulates endocytosis (Husebye et al., 2006; Lee et al., 2007; Marella et al., 2002; Triantafilou et al., 2004). In addition to binding PAMPs, TLRs bind damage-associated molecular patterns (DAMPs), which can elicit an inflammatory response in the absence of infection. Both TLR4 and PrP\textsuperscript{c} interact with the DAMPs heparan sulfate and hyaluronan (Johnson et al., 2002; Pan et al., 2002; Termeer et al., 2002). It is unclear which accessory proteins mediate the transfer of...
DAMPs to TLR4. Although we have not found PrP$^c$ to influence the inflammatory response to TLR signaling in response to PAMPs, it is intriguing to consider whether PrP$^c$ could be an accessory protein in TLR4 DAMP signaling. PrP$^c$ appears to be developmentally regulated in the brain and plays a role in many developmental functions. Additionally, PrP$^c$ has been shown to influence immune cell function, primarily in the periphery. We hypothesized that PrP$^c$ would influence the neuroinflammatory response in young mice, perhaps by acting as a scavenger receptor for TLR ligands. However, in our investigation of the inflammatory response to IC TLR 4 or 9 stimulation, we did not observe PrP$^c$–dependent differences in the acute neuroinflammatory response, as measured by cytokine production and glial activation.
Figure 4.1 Brain PrP<sup>C</sup> expression is influenced by age but not TLR4 or TLR9 stimulation. (A)

Prion protein (Prnp) transcript levels were measured in the brain, spleen and thymus of C57Bl/10 WT untreated mice at 2, 14 and 42 days old. Only brain tissue showed an age-dependent increase in Prnp expression. Housekeeping gene expression was averaged using Gusb, Actb and Rpl32. n=4-5 per group. (B) Prnp mRNA levels in WT neonatal and weanling brains were analyzed from 2 to 48 hpi after inoculation with either PBS or LPS. No differences in Prnp levels were observed. Data are presented as mean +/- SE. n=5-6 per group.
Figure 4.2 Tlr mRNA expression is influenced by age but not PrP<sup>c</sup> expression. Tlr transcript levels were measured in the brain (A), spleen (B) and thymus (C) of WT and PrP<sup>−/−</sup> untreated mice at 2, 14 and 42 days old. mRNA expression levels of Tlrs 3, 4, 7 and 9 increased steadily with age in the brain and spleen. A similar trend was observed in the thymus for Tlr4 and Tlr7 expression. No differences in basal Tlr mRNA levels were observed between WT and PrP<sup>−/−</sup> tissues. Housekeeping gene expression was averaged using Gusb, Actb and Rpl32. Data are presented as mean +/- SE. (D & E) At 12 hpi after TLR4 or 9 stimulation, Tlr4 and Tlr9 mRNA levels in WT and PrP<sup>−/−</sup> brains were examined. No significant PrP<sup>c</sup>-dependent differences were noted in neonatal (D) or weanling (E) mice. Data are presented as mean +/- SD. n=3-5 per group.
Figure 4.3 PrP² expression does not alter cytokine responses to TLR 4 or 9 stimulation in
neonatal brains. WT and PrP⁻/⁻ mice were inoculated with PBS, LPS or CpG intracerebrally (IC).
Uninoculated controls were used as an additional control group. Cytokine protein levels at 12
hpi were measured in neonatal brain tissue by multiplex. Representative cytokines are shown
here. WT data was previously shown in Figures 3.1 and 3.2. No significant differences in
cytokine production were observed between WT and PrP⁻/⁻ brains. Data are presented as mean
+/− SD. # indicates treatment group contains samples above the dynamic range (based on
standard curve). Outliers detected by Grubbs’ test were excluded. Statistical analysis was
completed by two-way analysis of variance with Sidak’s multiple comparisons test. For both
WT and PrP\(^{-}\) mice, data contain the combined results of two independent experiments. \(n=10-13\) per group.
Figure 4.4 PrP\textsuperscript{c} expression does not alter cytokine responses to TLR 4 or 9 stimulation in weanling brains. WT and PrP\textsuperscript{−/−} mice were inoculated with PBS, LPS or CpG intracerebrally (IC). Uninoculated controls were used as an additional control group. Cytokine protein levels at 12 hpi were measured in weanling brain tissue by multiplex. Representative cytokines are shown here. WT data was previously shown in Figures 3.1 and 3.2. No significant differences in cytokine production were observed between WT and PrP\textsuperscript{−/−} tissue. Data are presented as mean +/- SD. Outliers detected by Grubbs’ test were excluded. Statistical analysis was completed by two-way analysis of variance with Sidak’s multiple comparisons test. n=5-6 per group.
Figure 4.5 PrP<sup>c</sup> overexpression does not influence cytokine responses to TLR9 stimulation in weanling brains. Cytokine responses in Tg7 PrP<sup>c</sup> overexpressing mice were compared to responses in WT and PrP<sup>−/−</sup> weanling mice. WT and PrP<sup>−/−</sup> data are also shown in Figure 4.5. Brain cytokine levels were measured at 12 hpi by multiplex. Representative data are shown here. No significant differences in cytokine levels were detected between WT, PrP<sup>−/−</sup> and Tg7 mice. Data are presented as mean ± SD. Outliers detected by Grubbs' test were excluded. Statistical analysis was completed by two-way analysis of variance with Sidak's multiple comparisons test. n=5-6 per group.
Figure 4.6 PrP expression does not alter expression of glial activation markers in response to LPS or CpG. Expression of astrocytic and microglial activation markers was examined in WT and PrP−/− brains at 6 hours after TLR stimulation. Since a two-fold change is the smallest change that can be observed by qRT-PCR, differences in mRNA expression that were less than two-fold were not considered significant. No significant differences in expression of the glial activation markers Nos2, Cd80, Icam1 and Gpr84 were observed between WT and PrP−/− brains. n=5-7 per group.


CHAPTER FIVE

EXPERIMENTAL METHODS

Ethics statement

All animal research was carried out in adherence with protocols approved by the National Institutes of Health Rocky Mountain Laboratories Animal Care and Use Committee.

Animal models and inoculation of TLR agonists

All mice were housed and maintained by the Rocky Mountain Laboratories Veterinary Branch (Hamilton, MT). Mice were maintained under pathogen-free conditions with regular light/dark cycles and given food and water ad libitum. WT C57Bl/10 and PrP\(^{−/−}\) C57Bl/10 mice were inoculated at 36-48 hours of age. Newborn mice were anaesthetized by hypothermia prior to intracerebral (IC) inoculations using a Hamilton syringe with a 33-gauge needle. Three week old mice were anaesthetized by isoflurane inhalation prior to inoculation. Mice were inoculated once in each hemisphere with a solution volume of 3 µl per hemisphere. Mice were inoculated with one of two TLR agonists, lipopolysaccharide (LPS) or unmethylated CpG-rich oligonucleotides (CpG), or with a phosphate-buffered saline (PBS) control. Mice were weighed and amount of TLR agonist used was based on average weight at each age. For TLR stimulation, mice were inoculated with either 0.5 µg LPS per gram of body weight or 0.125 µg CpG per gram of body weight. For neonatal mice, this meant a total inoculum of 1 µg LPS or 0.25 µg (40 picomoles) CpG. For three week old mice, this translated to 3.8 µg LPS or 0.95 µg CpG. As an
additional control, another group of mice remained completely uninoculated. All experimental and control groups contained mice from multiple litters that were inoculated on different days.

Harvesting of tissues for mRNA and protein analysis

Prior to harvesting of tissues, all animals were anaesthetized by inhalation of isofluorane, followed by axillary incision and cervical dislocation at the specified time point. Brains were snap frozen in liquid nitrogen and stored at -80°C.

TLR agonists

TLR4 agonist ultra pure LPS (Cat. No. tlrl-3pelps) and TLR9 agonist phosphorothioated CpG type B [5’-tcc atg acg ttc acg tt-3’] (Cat. No. tlrl-1826) were purchased from InvivoGen. Agonist stocks were suspended in endotoxin-free water, aliquoted and stored at -20°C. Immediately prior to use, agonists were diluted in endotoxin-free, PBS-buffered solution.

Protein quantification

For protein quantification, brains were weighed and homogenized in Bio-Plex cell lysis buffer (Bio-Rad Cat. No. 171-304012) containing PMSF (Sigma Cat. No. P-7626) and Complete Mini Protease Inhibitor Cocktail (Roche Cat. No. 11836153001). Brains in cell lysis buffer were homogenized using Kontes pellet pestles (Fisher Scientific) and diluted to a final concentration of 300 mg/ml wet weight. Samples were centrifuged at 4,500 × g for 15 minutes at 4°C and supernatants collected for further analysis. Cytokine and chemokine protein levels in brain homogenate supernatants were analyzed using the Invitrogen Mouse Cytokine Twenty-Plex
Antibody Bead kit (Cat. No. LMC006) on a Bio-Rad Bio-Plex 200 system. Individual protein concentrations were calculated using standard curves generated from standards provided with the Twenty-Plex kit. IL-6 (Cat. No. M6000B) and CCL2 (Cat. No. MJE00) protein levels were also analyzed using R & D Systems ELISA kits. Individual protein concentrations were calculated using standard curves generated from standards provided with the ELISA kits.

Quantification of mRNA Expression by Real-Time PCR

Total RNA was extracted using the Qiagen RNeasy Mini Kit (Cat. No. 74106) per manufacturer’s instructions. RNA was then treated with DNase (Ambion Cat. No. AM2224) for 30 min at 37°C, followed by a final purification and concentration using the Zymo Research RNA Clean-up kit (Cat. No. R1018). Complimentary DNA (cDNA) was generated from the isolated RNA using the iScript cDNA Synthesis kit (Bio-Rad Cat. No. 170-8891). All primers were designed using Primer3 and were gene-specific in blast searches performed using the National Center for Biotechnology Information database. Real-time PCR was performed using iTAQ SYBR Green Supermix with ROX (Bio-Rad Cat. No. 1725852) on an Applied Biosystems PRISM 7900HT instrument. All samples were run in triplicate. The baseline was automatically set and the $C_T$ was manually set to intersect the mid-log phase of PCR curves at 0.19. Dissociation curves were used to verify that only a single gene product was amplified in each sample. RNA that was not reverse transcribed and water were used as negative controls. Primers used are listed in Table 6.1.
Preparation of brain tissue for flow cytometry

Animals were anaesthetized by inhalation of isofluorane, followed by perfusion through the left ventricle of the heart with ice cold 1x Hank’s balanced salt solution (HBSS) without calcium and magnesium (Gibco Cat. No. 14185). Whole brains were removed and sliced into several pieces using a razor. Weanling brain homogenates were then Dounce homogenized while neonatal brain homogenates were triturated using a 5 ml pipet. Neonatal and weanling brain homogenates were further triturated using a 20G needle. For samples that were enzymatically digested, brain homogenates were incubated in 0.05% Collagenase D (Roche Cat. No. 11 088 882 001), 0.09 U/ml Dispase I (Sigma Cat. No. D4818) and 0.025 U/ml DNase I (Sigma Cat. No. D4527) in 1x HBSS at room temperature for 30 minutes with continuous rocking. Neonatal tissue was digested in 5 mls per brain, 10 mls per brain was used for weanling tissue. Vigorous pipetting was used to dislodge any cells that may have adhered to the sides of tubes during enzymatic digestion. Cell suspensions were then placed on 0/30/70% Percoll gradients. Percoll (Sigma Cat. No. P4937) was diluted to the appropriate concentration using HBSS. One Percoll gradient was used per neonatal brain and two Percoll gradients per weanling brain. After centrifugation for 20 minutes at 4° C, the fraction at the 30/70% interface was removed for further analysis of CNS immune cells. For samples that were prepared using myelin depletion columns, brain homogenates were pre-incubated with myelin removal beads (Miltenyi Biotec Cat. No. 130-094-544) following manufacturer’s instructions. One neonatal brain homogenate was placed on an LS column (Miltenyi Biotec Cat. No. 130-042-401) while two LD columns (Miltenyi Biotec Cat. No. 130-042-901) were used per weanling brain homogenate.
Flow cytometric analysis of CNS populations ex vivo

After generation of single cell suspensions using either enzymatic digestion and Percoll gradients, or myelin depletion columns, cells were then counted by hemocytometer. Aqua Live/Dead staining (Life Technologies Cat. No. L34657) was performed at this time on some samples. During development of the flow cytometry protocol, as described in Chapter 4, samples of the same age and treatment group were pooled. For flow cytometry experiments described in Chapter 2, samples were not pooled, permitting the analysis of biological replicates. Neonatal and weanling samples that were compared to one another were examined in the same experiment, as were PBS- and LPS-treated samples. Samples were plated onto 96-well plates. Similar numbers of cells were added to each well. Cells were fixed in 2% paraformaldehyde, then permeabilized in 0.1% saponin/2% bovine serum albumin (BSA)/1x PBS. Samples were incubated in an Fc blocking solution containing rat anti-mouse CD16/CD32 Fcγ III/II antibody (BD Pharmingen Cat. No. 553142) in 2% donkey serum/0.1% saponin/2% BSA/1x PBS. Cells were incubated with fluorescently-conjugated antibodies at room temperature. After washing twice, cells were resuspended in PBS and analyzed on a FACS Aria flow cytometer (BD Biosciences) using FACSDiva software (BD Biosciences). Data were analyzed using FCS Express. A list of antibodies used is given in Table 6.2.

Harvesting and preparation of spleen tissue for flow cytometry
Spleens were Dounce homogenized, then incubated in Ammonium-Chloride-Potassium (ACK) buffer to lyse red blood cells. Samples were then centrifuged, resuspended in PBS, and single cell suspensions were prepared for flow cytometry as described for brain cells (above).
## Table 6.1 Primers used for qRT-PCR

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Forward primer</th>
<th>Reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actb</td>
<td>CAGCTTCTTTGCAGCTCCTT</td>
<td>CACGATGGAGGGGAATACAG</td>
</tr>
<tr>
<td>Rpl32</td>
<td>ACATCGGTTATGGGAGCAAC</td>
<td>CACCTCCAGCTCTTGGACAT</td>
</tr>
<tr>
<td>Gapdh</td>
<td>AACGACCCCCTTCATTGAC</td>
<td>TCCACGACATACCTGAGCA</td>
</tr>
<tr>
<td>Gusb</td>
<td>CAATGAGCCTTCCCTGCTC</td>
<td>CTGCATCATATTGGCGTTG</td>
</tr>
<tr>
<td>Cd3e</td>
<td>GAGCACCCTGCTACTCCTTG</td>
<td>TGAGCAGCCTGATTCTTTCA</td>
</tr>
<tr>
<td>Cd80</td>
<td>CCTTGCCGTTACAACCTCCTC</td>
<td>CAGGCCCAGGATGATAAGAG</td>
</tr>
<tr>
<td>Cd8a</td>
<td>TCAGTTCTGTCGTGCCAGTC</td>
<td>GCGGACAATCTTTCTGGTCTC</td>
</tr>
<tr>
<td>Ela2</td>
<td>CTTCGAGAATGGCGTTTACC</td>
<td>ACGTTGCGTTATGGTGAGC</td>
</tr>
<tr>
<td>F4/80</td>
<td>ACAAGTGCTCCCTCCGTGCT</td>
<td>AACATGTGCTTCCACAGTC</td>
</tr>
<tr>
<td>Gfap</td>
<td>CGTTTCCTCTTGTCTGAATGAC</td>
<td>TCGCCGTGTCCTCCTG</td>
</tr>
<tr>
<td>Gpr84</td>
<td>CTGACTGCCCTCAAAAGAC</td>
<td>GGAGAAGTGGCATCTGAGC</td>
</tr>
<tr>
<td>Icam1</td>
<td>AGGGTGGGATTGTTTCTTA</td>
<td>CTTACAGGCAGGAAACAGG</td>
</tr>
<tr>
<td>Ifnb1</td>
<td>AGCAGTGGGTAGGAATGAGAC</td>
<td>TCCACGTCAATCTTTGAG</td>
</tr>
<tr>
<td>IL-6</td>
<td>CCGAGAGAGGAATTCACAG</td>
<td>TCCACGATTTCCCAGAGAAG</td>
</tr>
<tr>
<td>Cxcl10</td>
<td>CAGTGAAGATAGGAGGGCATAGG</td>
<td>CTCAACACGTGGGCGAGGAT</td>
</tr>
<tr>
<td>Itgax</td>
<td>ATGTTGGAGGAAAGCAAATGG</td>
<td>TGGGGCTGACTTAGGAGGAGA</td>
</tr>
<tr>
<td>Ccl2</td>
<td>CCCACTACCTGCTACTTAC</td>
<td>TCTGGACCATACTTCTT</td>
</tr>
<tr>
<td>Ccl3</td>
<td>ACCATGACACTCTGCAACCA</td>
<td>GATGAATTGGCGTGAAAG</td>
</tr>
<tr>
<td>Nos2</td>
<td>GACGGTAGGCGAGAATTGG</td>
<td>CACATGCAAGGAAGGGAACT</td>
</tr>
<tr>
<td>Prnp</td>
<td>GGACCGCTACTACCGTGAAA</td>
<td>TCATCTCACATCGGTCTCG</td>
</tr>
</tbody>
</table>

~ 94 ~
<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Sequence</th>
<th>Reverse Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slamf7</td>
<td>GCAGAACTCAGCAATGTCCA</td>
<td>GAAAGCCCAACCTCGATACA</td>
</tr>
<tr>
<td>Tlr3</td>
<td>AGCTTTGCTGGGAACCTTTCA</td>
<td>ATCGAGCTGGGTGAGATTTG</td>
</tr>
<tr>
<td>Tlr4</td>
<td>GGCAGCAGGTGGAATTGTAT</td>
<td>AGGATTGAGGCTTTTCCAT</td>
</tr>
<tr>
<td>Tlr7</td>
<td>GGCATCCCACAAACACCAC</td>
<td>TTGGACCCAGTAGAACAGG</td>
</tr>
<tr>
<td>Tlr8</td>
<td>TCGTCTTGACCATTTGTGGA</td>
<td>AATGCTCCATTGCGGATTTG</td>
</tr>
<tr>
<td>Tlr9</td>
<td>ACTTCGTCACCTGTCCAAC</td>
<td>TCATGTGGCAAGAAGTGC</td>
</tr>
<tr>
<td>Tnf</td>
<td>CCACCACGCTCTCTCTCTCACC</td>
<td>GAGGGTCTGGCCATAGAA</td>
</tr>
</tbody>
</table>


~ 95 ~
<table>
<thead>
<tr>
<th>Antigen</th>
<th>Clone</th>
<th>Vendor</th>
<th>Cat. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD11a-eFluor450</td>
<td>M17/4</td>
<td>eBiosciences</td>
<td>48-0111</td>
</tr>
<tr>
<td>CD11b-AF700</td>
<td>M1/70</td>
<td>eBiosciences</td>
<td>56-0112-82</td>
</tr>
<tr>
<td>CD11b-V500</td>
<td>M1/70</td>
<td>BD Horizon</td>
<td>562127</td>
</tr>
<tr>
<td>CD172a-FITC</td>
<td>P84</td>
<td>BD Pharmingen</td>
<td>560316</td>
</tr>
<tr>
<td>CD200R-PerCP-eFluor710</td>
<td>OX110</td>
<td>eBiosciences</td>
<td>46-5201</td>
</tr>
<tr>
<td>CD45-PE</td>
<td>30-F11</td>
<td>BD Pharmingen</td>
<td>553081</td>
</tr>
<tr>
<td>CD86-AF700</td>
<td>GL1</td>
<td>BD Pharmingen</td>
<td>560581</td>
</tr>
<tr>
<td>F4/80-APC</td>
<td>BM8</td>
<td>eBiosciences</td>
<td>17-4801-82</td>
</tr>
<tr>
<td>GFAP-AF488</td>
<td>--</td>
<td>Cell Signaling</td>
<td>3655</td>
</tr>
<tr>
<td>LY6C-AF700</td>
<td>AL-21</td>
<td>BD Pharmingen</td>
<td>561237</td>
</tr>
<tr>
<td>SLAMF7-Fluorescein</td>
<td>--</td>
<td>R&amp;D Systems</td>
<td>FAB4628F</td>
</tr>
</tbody>
</table>
CHAPTER SIX

CONCLUDING REMARKS

In humans, gestational infections have been linked to later neurological illness in offspring. The correlation between infection and neurological illness has been most often made for schizophrenia, a disease that usually does not manifest itself until late adolescence or early adulthood. While such complex neurological diseases cannot be fully reproduced in animal models, specific pathological symptoms can. For example, in animal models of schizophrenia, perinatal immune stimulation can replicate specific behavioral and cognitive disabilities, including the delayed onset.

The underlying mechanisms that may connect early infection with later neurological illness are unknown. In humans, a variety of infectious agents, including viruses, bacteria and parasites have been associated with neurological illness. In animal models, inoculation with infectious agents, TLR ligands or the cytokine IL-6 can lead to neurodevelopmental abnormalities. Collectively, this suggests it is a generalized response to infection that may increase one’s risk of neurological illness. In this respect, the developing immune response in the brain is of particular interest.

To better understand how the neonatal immune response differs from other ages, it is helpful to directly compare the response of neonatal immune cells with those from older animals that are known to have a more mature immune system. Since weanling mice are less susceptible to neurological infection than neonatal mice, we compared the neonatal cytokine response to IC TLR4 or TLR9 stimulation with that of weanling mice.
In our comparisons of the cytokine response at each age, we found that production of many cytokines was increased in neonatal brains. This included pro-inflammatory cytokines that are elevated in a variety of neurological conditions, such as IL-1b, TNF and IL-6, as well as cytokines whose roles in neuroimmunity are not well characterized, such as IL-5. While some of these cytokines, such as IL-6, have previously been linked to neurodevelopmental illness in animal models of disease, others, such as IL-5, have not. Knowledge of cytokines that are elevated during the neonatal neuroinflammatory response may lead to important insights into their impact on neurodevelopment. The neonatal cytokine response we observed in the brain differed from what has been reported in some other tissues after TLR stimulation, including the ability to produce large amounts of strongly pro-inflammatory cytokines such as IL-1b and TNF. In future studies, it will be interesting to directly compare the production of these cytokines in the brains and peripheral tissues of neonates. It is somewhat surprising that their expression would be inhibited to a greater extent in peripheral tissues, than in the brain, where there is a greater risk of long-term damage.

Microglia and astrocytes are important immune- and TLR-responsive cells in the brain parenchyma. In addition, macrophages inhabit the perivascular spaces surrounding brain tissue. We sought to characterize the expression of activating and inhibitory receptors on these cells at each age. Although we came up against several unexpected obstacles in our attempts to characterize CNS immune-responsive populations ex vivo using flow cytometry, we did observe age-specific differences in expression of activating $\beta_2$-integrins and inhibitory CD172a on microglia. Rather unexpectedly, considering the more amoeboid phenotype of neonatal microglia, neonatal microglia did not express increased amounts of all activating proteins.
examined, nor did they express lower levels of some of the inhibitory proteins examined, when compared with weanling microglia. In future studies, it would be interesting to directly compare regulation of microglial activation at each age, as our data could suggest some age-dependent differences in microglial regulation.

We also noted relatively high expression of SLAMF7 on neonatal microglia. Since many immunoregulatory proteins are expressed at lower levels on microglia than on other immune cell populations, it will be particularly interesting to examine how SLAMF7 influences neonatal microglial activation, as it may be particularly important for their function. Since microglial SLAMF7 has not been previously described, and SLAMF7 can have both activating and inhibitory functions, its role in microglial physiology is not immediately clear.

In addition, we observed age-specific differences in the ratios of different CD45$^{hi}$ populations in the brain, which could have important consequences for the immune response under a variety of conditions at each age.
REFERENCES


Angelone, D.F., et al., 2006. Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo. Pediatric Research. 60, 205-209.


Bechmann, I., Galea, I., Perry, V.H., 2007. What is the blood-brain barrier (not)? Trends in Immunology. 28, 5-11.

Belderbos, M.E., et al., 2009. Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: Low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clinical Immunology. 133, 228-237.


Bueler, H., et al., 1993. MICE DEVOID OF PRP ARE RESISTANT TO SCRAPIE. Cell. 73, 1339-1347.


~ 101 ~


Field, E.J., Joyce, G., Keith, A., 1969. FAILURE OF INTERFERON TO MODIFY SCRAPIE IN MOUSE. Journal of General Virology. 5, 149-&.

Ford, A.L., et al., 1995. NORMAL ADULT RAMIFIED MICROGLIA SEPARATED FROM OTHER CENTRAL- NERVOUS-SYSTEM MACROPHAGES BY FLOW CYTOMETRIC SORTING - PHENOTYPIC DIFFERENCES
DEFINED AND DIRECT EX-VIVO ANTIGEN PRESENTATION TO MYELIN BASIC PROTEIN-REACTIVE CD4(+) T-CELLS COMPARED. Journal of Immunology. 154, 4309-4321.


Hernangómez, M., et al., 2012. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. GLIA. 60, 1437-1450.


Manson, J.C., et al., 1994. 129/OLA MICE CARRYING A NULL MUTATION IN PRP THAT ABOLISHES MESSENGER-RNA PRODUCTION ARE DEVELOPMENTALLY NORMAL. Molecular Neurobiology. 8, 121-127.


Rudge, J.S., et al., 1995. CHANGES IN NEUROTROPHIC FACTOR EXPRESSION AND RECEPTOR ACTIVATION FOLLOWING EXPOSURE OF HIPPOCAMPAL NEURON ASTROCYTE COCULTURES TO KAINIC ACID. Journal of Neuroscience. 15, 6856-6867.


Zhang, G.X., et al., 2002. Parenchymal microglia of naive adult C57BL/6J mice express high levels of B7.1, B7.2, and MHC class II. Experimental and Molecular Pathology. 73, 35-45.